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The vitamin A metabolite retinoic acid (RA) regulates potent anticarcinogenic 
activities and it is well established that these activities are mediated by retinoic acid 
receptors (RAR), ligand-inducible transcription factors that are members of the 
superfamily of nuclear hormone receptors.  Transcriptional activation of RAR has 
been shown to trigger differentiation, cell cycle arrest, and apoptosis. However, in 
some cancers, RA facilitates rather than inhibits cell growth, but the basis for 
development of RA-resistance remains incompletely understood. Here we show that 
the pro-proliferative activities of RA are mediated through a different nuclear receptor, 
the peroxisome proliferator-activated receptor β/δ (PPAR β/δ). The data show that 
partitioning of RA between the two receptors is cell-specific: in RA-resistant cells, RA 
activates PPAR β/δ and functions as a survival factor, while in others, it operates 
through RAR and triggers apoptosis. We demonstrate that the partitioning RA 
between its two receptors is regulated by two intracellular lipid binding proteins, 
cellular retinoic acid binding protein II (CRABP-II ) and fatty acid binding protein 5 
(FABP5) which target RA to RAR and PPAR β/δ, respectively.  The expression ratio 
of the two binding proteins in cells thus determines cellular responses to RA.  The data 
demonstrate that both in cultured cells and in transgenic mice models of breast cancer, 
a high CRABP-II/FABP5 ratio targets RA to RAR, thus upregulating growth 
   
inhibitory genes, including the cell cycle control protein BTG2, inducing the cleavage 
of the proapoptotic gene caspase 3, and suppressing carcinoma growth.  Conversely, 
RA is targeted to PPAR β/δ in cells that express a low CRABP-II/FABP5 ratio, 
thereby enhancing transcription of pro-proliferative genes such as PDK-1, a key 
component of the Akt survival pathway, and acting as a pro-carcinogenic agent. 
Finally, we show that modulating the relative expression levels of the two binding 
proteins in cells and in vivo, results in profound changes in biological responses to 
RA, thus committing the cell to either life or death. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Retinoid Transport and Metabolism: 
 
 Retinoic acid (RA), a metabolite of vitamin A, plays critical roles in embryonic 
development, and in growth and differentiation in adult mammals.  Vitamin A is 
obtained through the diet as plant-derived provitamin A carotenoids, or as preformed 
retinyl esters from animal sources (Gamble, Shang et al. 1999; Vogel, Gamble et al. 
1999). After absorption by mucosal cells in the intestine, carotenoids are converted to 
retinal by carotene cleavage enzyme.  Retinal is then converted to retinol by retinal 
reductase.  Dietary retinyl esters are hydrolized to yield free retinol and a free fatty 
acid though the action of retinyl ester hydrolases.  In the enterocyte, retinol, 
originating from either source, is esterified to retinyl esters by lecithin: retinol 
acyltransferase (LRAT), packaged into chylomicrons and secreted into the lymphatic 
system.  Retinoids are mainly stored in stellate cells (Ito cells) in the liver as retinyl 
esters in lipid droplets (Gamble, Shang et al. 1999; Vogel, Gamble et al. 1999).  Upon 
depletion of serum vitamin A, retinol is mobilized and secreted to serum from these 
hepatic stores.  It is well established that, except for the function of vitamin A in 
vision, which is dependent upon the 11-cis-retinaldehyde metabolite, most other 
biological roles of the vitamin are exerted by retinoic acids, which are synthesized 
from retinol through the action of two classes of enzymes: retinol dehydrogenases, 
which oxidize retinol to retinaldehyde, and retinal dehydrogenases which subsequently 
catalyze the oxidation od retinaldehyde to RA.  
   3 
Due to their hydrophobic nature, nature, retinoids are poorly soluble in 
aqueous environments and their solubilization and transport through aqueous phases is 
accomplished by their association with soluble proteins. Several proteins function to 
transport hydrophobic molecules in extracellular spaces, including serum albumin and 
retinol binding protein (RBP), which transports retinol in the blood. In the cell, the 
active metabolite of retinol, RA, is bound by CRABP-I, which is thought to facilitate 
RA catabolism, and CRABP-II, which, in the presence of ligand, has been shown to 
translocate to the nucleus and deliver RA to the ligand-activated transcription factors 
termed the retinoic acid receptors (RAR) (Dong, Ruuska et al. 1999; Budhu and Noy 
2002; Sessler and Noy 2005).  
In addition to CRABPs, the family of intracrellular lipid-binding proteins 
(iLBP) also contains 9 known isotypes of proteins referred to as fatty acid binding 
proteins (FABP) which associate with a wide spectrum of long chain fatty acids and 
some of their metabolites.  The exact functions and the nature of the physiologically 
meaningful ligands for these proteins are incompletely understood but it has been 
reported that, similarly to CRABP-II, some FABPs cooperate with specific ligand-
activated transcription factors.  Of special interest in the context of this thesis, it has 
been demonstrated that transcriptional activation by PPARβ/δ is supported by FABP 
5 (FABP5, K-FABP, eFABP, mal1). Like other FABPs, FABP5 can bind various 
hydrophobic compounds, but it moves to the nucleus only upon association with 
ligands that activate PPARβ/δ. It thus shuttles cognate ligands from the cytosol to 
PPARβ/δ in the nucleus and enhances the receptor’s activity (Tan, Shaw et al. 2002). 
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1.2 Nuclear Hormone Receptors: 
 
The biological roles of the two active RA isomers, all-trans-RA and its 9-cis 
isomer, including regulation of cellular proliferation, differentiation and embryonic 
development are mediated through binding of two members of the family of nuclear 
hormone receptors, the retinoid X receptors (RXR) and RAR (Chambon 1996; Pfahl 
and Piedrafita 2003). Nuclear hormone receptors are ligand-activated transcription 
factors that bind to specific DNA sequences in the promoter region of inducible genes 
and act to modify gene transcription (Mangelsdorf, Thummel et al. 1995).  The 
nuclear receptor family has been classified into 6 subclasses based on sequence 
homology and evolutionary considerations (Gronemeyer, Gustafsson et al. 2004).  
Subfamily 3 contains steroid receptors, such as estrogen receptor (ER), androgen 
receptor (AR), and glucocorticoid receptor (GR). Steroid receptors usually act as 
homodimers and interact with inverted DNA consensus sequences.  Subfamilies 1 and 
2 contain various receptors including the retinoid receptors RAR and RXR, vitamin D 
receptor (VDR), and peroxisome-proliferator-activated receptor (PPAR) (Gronemeyer, 
Gustafsson et al. 2004).  The non-steroid receptors usually form heterodimers with a 
common binding partner, namely RXR. These heterodimers bind to DNA recognition 
sequences organized as direct repeats. Notably, some nuclear receptors termed orphan 
receptors to denote that the ligands that activate them (if such exist) are unknown. 
Work proposed here focuses on two nuclear receptors - RAR and PPARβ/δ.     
   
 
 
 
Figure 1.1 Illustration of functional domains of nuclear receptors 
            AF-1 AF-2 
DNA Binding Domain Ligand Binding Domain 
A/B D E F C C N 
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Nuclear hormone receptors share a common structural organization composed 
of modular domains A-F shown in figure 1.  The amino terminal A/B region contains 
one of the receptors activation functions responsible for basal activation (i.e. ligand-
independent activation) while a second ligand-dependent activation domain is located 
in the carboxy-terminal ligand-binding domain (LBD, region E)(Chambon 1996; van 
der Saag 1996).  The LBD carries out multiple functions.  It binds ligand, and contains 
a dimerization region as well as a region that mediates interactions with a variety of 
accessory proteins.  Domain C contains two zinc finger motifs that allow for DNA 
binding by the receptor while the D domain is the hinge region conferring protein 
flexibility.  The F domain is present in only some of the nuclear hormone receptors 
including RAR, however its function is unknown (Pfahl and Piedrafita 2003). 
 In the absence of ligand, nuclear receptors such as TR and RAR bind to their 
response elements and associate with corepressor complexes (e.g. nuclear receptor 
corepressor-NcoR and silencing mediator of retinoid and thyroid receptors-SMRT).  
Corepressor complexes keep the chromatin structure surrounding the promoter in a 
compact and inactive state (Blanco, Wang et al. 1995; Chen and Evans 1995).  Upon 
ligand binding by the receptor, the corepressors dissociate and the receptor confers a 
transcriptionally active conformation.  This active receptor signals transcription 
initiation by recruiting auxiliary proteins called coactivators.  Initially, remodeling 
enzymes, such as the SWI/SNF complex, use the energy of ATP to reposition 
nucleosomes, exposing sites of transcription initiation (Horn and Peterson 2002; 
Lorch, Maier-Davis et al. 2006). Proteins that modify and open the chromatin template 
that, in turn, allows the basal transcription factors to bind the promoter. Proteins such 
as p300/CBP acetylate nucleosomal histones that loosen the chromatin template by 
catalyzing histone acetylation (Boube, Joulia et al. 2002).  Other coactivators, such as 
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the Mediator (also known as thyroid hormone receptor associated proteins (TRAP) or 
vitamin D receptor interacting proteins (DRIP)), function to bridge receptors directly 
to the basal transcription machinery, stabilizing transcription initiation (Rachez, 
Gamble et al. 2000; Rachez and Freedman 2001).  Mediator is a large, multi-subunit 
complex that contains members of the basal transcription machinery. Thus, ligand 
binding to the nuclear receptor is the critical step signaling initiation of transcription. 
Regulation of such a critical step will be an important aspect of cellular control.   
Two class II nuclear hormone receptors, RAR and RXR, bind retinoic acids 
with distinct ligand-binding specificities.  RAR is activated by both 9-cis-RA  and all-
trans-RA while RXR is activated by only 9-cis-RA (Giguere 1994).  Both retinoid 
receptors exist as three isotypes (α, β, γ); each expressed from different genes and 
display different expression profiles, suggesting that they have distinct roles.  Each 
isotype can be found as different isoforms as a result of differential promoter usage 
and alternative splicing (Leroy, Nakshatri et al. 1991). 
 
                  
 
 
 
 
Figure 1.2 Structures of 9-cis-retinoic acid and all-trans-retinoic acid 
 
RAR-RXR heterodimers bind to DNA response elements comprised of a direct repeat 
of the hexanucleotide half-site 5’-AGGTCA-3’ separated by either two or five 
nucleotides (Umesono, Giguere et al. 1988).  Target genes of retinoid receptors, such 
as CYP26a, control cellular processes involved in differentiation, apoptosis, and cell 
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cycle control.  RXR functions as a common binding partner for all class II nuclear 
receptors and is considered the “master regulator” for non-steroid receptor signaling 
(Umesono, Giguere et al. 1988).  
 Most of the isoforms of both RARs and RXRs are expressed in breast cells.  It 
has been reported that the retinoid receptor profiles in cells are altered during 
progression of various cancers (Gudas 1992).  Most notably, the expression of RARβ2 
is markedly down-regulated in lung carcinoma, head and neck squamous cell 
carcinoma, and breast carcinoma.  It was also reported that RA-dependent induction of 
RARβ correlates with the growth inhibitory effect of retinoids in several cancer cell 
lines, including some mammary carcinomas, and that RA-resistant breast cancer cells 
acquire RA sensitivity upon ectopic expression of RARβ (Verma, A. K., E. A. 
Conrad, et al. 1982).  These observations suggest that the RARβ isoform is 
specifically involved in mediating the growth inhibitory effects of RA.   
 
 
1.3 Peroxisome Proliferator Activated Receptors (PPARs): 
 
Three different isotypes of PPAR are know to exist in mammals. These 
isotypes display different tissue distributions as well as cellular function. PPARα is 
expressed in liver, kidney, muscle and heart, as well as in tissues with high rates of 
fatty acid catabolism.  Consequently, activation of PPARα lowers serum lipid levels, 
and synthetic ligands for this receptor are efficient therapeutic agents in treatment of 
hyperlipidemia (Forman, Tontonoz et al. 1995).  PPARγ is expressed predominantly in 
adipose tissue and macrophages, where it is involved in adipocyte differentiation, 
regulation of sugar and lipid homeostasis, and control of inflammatory responses 
(Devchand, Keller et al. 1996). PPARβ/δ is ubiquitously expressed with particularly 
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high level of expression found in brain, adipose tissue, skeletal muscle, and skin (Di-
Poi, Tan et al. 2002).  This receptor is involved in neuronal development, 
inflammation, skeletal muscle lipid oxidation, keratinocyte differentiation, epidermal 
barrier recovery, and lipid synthesis for keratinocyte proliferation (Icre et al., 2006; 
Michalik and Wahli; 2007).  PPARβ/δ expression in skin is increased in 
hyperproliferative lesions, and in response to inflammatory cytokines during skin 
injury (Icre, Wahli et al. 2006; Michalik and Wahli 2007). Studies using transgenic 
mice have revealed evidence of PPAR involvement in numerous disease states 
(Desvergne and Wahli 1999).  
Several biological lipids have been proposed to serve as endogenous biological 
ligands for PPARs.  Recent studies have suggested that LTB4 may have activity as an 
endogenous ligand for PPAR . As PPARα is involved in fatty acid oxidation, it has 
been suggested that LTB4 acts in a negative feedback manner by inducing the 
transcription of genes involved its own metabolism (Devchand, Keller et al. 1996; 
Latruffe and Vamecq 1997). The cyclopentanone prostaglandin 15-deoxy PGJ2 (15D-
PGJ2), which is the metabolite of the prostaglandin D2, has been suggested to function 
as an endogenous ligand for PPAR  (Forman, Tontonoz et al. 1995; Wayman, Ellis et 
al. 2002).  However, the involvement of these and other potential ligands in the 
activities of PPARs in vivo has not been established, and these receptors remain 
classified as “orphan receptors”. 
Our research project has centered primarily on PPARβ/δ. In contrast to 
PPARα and PPARγ, the physiological functions of PPARβ/δ are poorly understood. 
This may in part be due to the ubiquitous expression of PPARβ/δ as well as the 
difficulty in identifying its physiological ligands. However, synthetic ligands such as 
L-165041 and GW0470 have been shown to directly activate PPARβ/δ and induce 
downstream gene activity (Berger, Bailey et al. 1996). 
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PPARβ/δ was recently identified as a target of the tumor suppressor APC in 
colorectal cancer cells. PPARβ/δ is highly expressed in cells with inactive APC 
expression. A PPARβ/δ  null colorectal cell line showed a significant reduction in 
ability to form tumors in nude mice compared to PARβ/δ heterozygous colorectal 
cancer cells (He, Barak et al. 2003). PPARβ/δ expression in skin is increased in 
hyperproliferative lesions, and in response to inflammatory cytokines during skin 
injury.  Elevation of PPARβ/δ expression in keratinocytes during skin injury is 
accompanied by production of an (unknown) endogenous ligand(s), resulting in 
protection against apoptotic signals and in enhancement of skin repair (Michalik and 
Wahli 2007).  These anti-apoptotic activities are mediated, at least in part, by the 
ability of PPARβ/δ to directly upregulate the expression PDK1, thereby activating the 
survival factor Akt1 and protecting keratinocytes from apoptosis induced by cytokines 
such as TNFα (Di-Poi et al., 2002; Icre et al, 2006; Tan et al., 2004, Burdick et al, 
2006). 
1.4 Intracellular Lipid Binding Proteins: 
 
It has been reported that several proteins in the intracellular lipid binding 
protein (iLBPs) family are capable of modulating the activities of NHRs. This protein 
family contains more than 14 members (see Table 1), including the fatty acid binding 
proteins (FABP), the cellular retinoic acid binding proteins (CRABP), and cellular 
retinol binding proteins (CRBPs) (Banaszak, Winter et al. 1994). The iLBPs have 
similar genomic organizations, consisting of four exons with total gene lengths of 5kB 
(Bernlohr, Simpson et al. 1997). The iLBPs are characterized by their similarity in 
size—roughly 14-16 KD, their highly conserved three-dimensional structure, and by 
their ability to bind small hydrophobic molecules (see Table 1)(Coe and Bernlohr 
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1998; Noy 2000). All members of this family bind a single hydrophobic ligand, except 
for L-FABP, which can bind two oleate molecules (Thompson, Ory et al. 1999). 
 FABPs include binding proteins, which were named according to the tissue 
they were first isolated in, are expressed abundantly in in cells involved in lipid 
metabolism, constituting 1-6% of total cytoplasmic protein (Bernlohr, Simpson et al. 
1997). FABPs are more promiscuous than CRABPs and they bind a variety of fatty 
acids and fatty acid derivatives (Sweitzer, Love et al. 2000; Tan, Shaw et al. 2002) 
displaying ligand-binding selectivities reminiscent of those of PPARs. Thus, similar to 
PPARs the biological meaningful ligands for FABPs are unknown.  
 
Table 1  iLBP tissue expression and distribution. 
 
Common Name Other Names Expression 
CRABP-I  Ubiquitously expressed in the adult and 
embryo 
 
CRABP-II 
 Skin, uterus, ovary, and choroids plexus, 
widely expressed in the embryo 
 
CRBP-I 
 
 Ubiquitously expressed in the adult tissues 
with high levels in the ovary, pancreas, 
pituitary ad adrenal glands, fetal liver 
CRBP-II  Adult intestine, fetal kidney 
CRBP-III  Adult kidney, liver, spleen, lymph nodes, and 
appendix 
FABP2 IFABP Intestine 
FABP4 AFABP 
AP2 
Adipose tissue, macrophages 
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Table 1 (Continued) 
 
FABP5 KLBP 
eFABP 
FABP5 
Mal1 
Endothelial cells, adipose tissue, lens, lung, 
brain, mammary glands, placenta, heart, 
skeletal muscle, intestine, testis, retina, and 
abnormal skin 
FABP1 LFABP Liver, intestine, kidney, and lungs 
FABP3 M-FABP 
MDGI 
HFABP 
 
Heart, mammary gland, and skeletal muscle  
FABP7 BLBP 
MRG 
BFABP 
 
Brain and olfactory bulb 
FABP6 BABP 
ILBP 
Gastrotropin 
 
Ileum 
FABP9 TLBP Testis 
FABP8 MLBP 
PMP2 
My-FABP 
 
Schwann cells 
 
Table 1  iLBP tissue expression and distribution. 
 
CRABPs display distinct tissue distribution; CRABP-II, which is widely 
distributed in the embryo, is expressed in the adult mainly in keratinocytes, in sertoli 
cells in the testis, at the uterus at particular stages of the estrus cycle and during 
pregnancy, and in the choroid plexus (Ong, Newcomer et al. 1994; Zheng and Ong 
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1998).  In contrast, CRABP-I is widely distributed in the adult (Ong, Newcomer et al. 
1994).  Both proteins bind specifically to all-trans-RA with Kd values of 0.06 nM and 
0.13 nM for CRABP-I and CRABP-II, respectively (Dong, Ruuska et al. 1999). A sub 
family of the intracellular lipid binding proteins is the family of fatty acid binding 
proteins (FABPs) which were named according to the tissue they were first isolated in. 
Currently there are nine known members of the FABP family.   
 
 
1.5 CRABP and FABP Function: 
 
Traditionally, it has been thought that FABPs play a passive role in solublizing 
their ligand (Ong, Newcomer et al. 1994).  However, it is becoming increasingly clear 
that these binding proteins play more specific roles in modulating signaling by these 
ligands.  The presence of CRABP-I has been shown to correlate with a decreased 
ability of F9 teratocarcinoma cells to differentiate in response to RA and with 
enhanced RA degradation (Gudas 1992).  Therefore, it has been suggested that 
CRABP-I functions to activate RA degradation pathways or to sequester it from 
binding to nuclear receptors.  A more specific role for this protein has yet to be 
discovered.  
Current evidence suggests that CRABP-II functions by directly delivering RA 
to RAR in the nucleus, thereby facilitating the ligation of the receptor and augmenting 
its transcriptional activities (Dong, Ruuska et al. 1999; Budhu and Noy 2002; Sessler 
and Noy 2005). Our lab has shown the mechanism by which CRABP-II translocates 
from the cytosol to the nucleus upon binding of RA leading to a transcriptional 
enhancement of RAR. Our lab and others have also found that CRABP-II enhances 
the RA-induced transcriptional activity of RAR in cells. The ability of  CRABP-II to 
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potentiate activity of RAR stems from its ability to channel RA to the receptor, which 
results in facilitation of the formation of the active form of RAR.  
It has been demonstrated that over-expression of CRABP-II dramatically 
enhances the responsiveness of mammary carcinoma cells to RA-induced growth 
inhibition, while diminished expression of the protein results in RA resistance (Budhu 
and Noy 2002; Donato and Noy 2005). We have also shown that CRABP-II inhibits 
mammary tumor growth in two different mouse models of cancer that are known to be 
RA-resistant. Our observations, as well as others, indicate that the level of expression 
of CRABP-II in several breast cancer cell lines and mouse models correlates with the 
efficiency of RA-induced growth inhibition, suggesting that down-regulation of 
CRABP-II is associated with development of RA resistance (Budhu and Noy 2002; 
Manor, Shmidt et al. 2003).  
The evidence suggesting that CRABP-II acts as a coregulator of RAR raises 
the possibility that other members of the iLBP family may cooperate with nuclear 
receptors. It was reported that some FABPs act in concert with PPARs and that this 
activity is highly selective for particular FABP-PPAR pairs: FABP3 activates PPARα, 
FABP4 specifically enhances the activity of PPAR , while FABP5 activates PPARβ/δ 
(Tan, Shaw et al. 2002). It was shown that both the ligand-induced nuclear localization 
of the FABPs and their ability to enhance transcriptional activity are highly selective 
for the ligand of a particular PPAR isotype. This is so despite the apparent lack of 
selectivity in ligand binding by the FABPs. These observations suggest that FABPs 
employ different modes of binding toward different ligands (Tan, Shaw et al. 2002). 
Interestingly, it has been reported that RA binds to PPARβ/δ with nanomolar affinity, 
modulates the conformation of the receptor, promotes interaction with the coactivator 
SRC-1, and efficiently activates PPARβ/δ-mediated transcription (Shaw, Elholm et al. 
2003).  These observations suggest that RA may be functioning through two distinct 
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nuclear receptors, the classical RA receptor RAR and PPARβ/δ.  The involvement of 
iLBPs in the transcriptional activities of nuclear receptors suggest further that 
regulation of the transcriptional activity of RA may be mediated by the ilBPS that 
specifically cooperate with RAR and PPARβ/δ, namely CRABP-II and FABP5. 
 
 
1.6 Mouse Model:  
 
To examine the roles of RA in mammary cancer development, we used the 
transgenic mouse model of breast cancer MMTV-neu.  In these mice, Neu/Erb-B2, 
which encodes for a member of the growth factor tyrosine kinase receptor family, is 
specifically over-expressed in mammary tissue, resulting in spontaneous development 
of mammary tumors in 100% of female mice (Guy, Webster et al. 1992).  
Amplification of this gene has been observed in a significant proportion of primary 
human breast cancers (King, Kraus et al. 1985; Yokota, Yamamoto et al. 1986), and a 
strong correlation has been established between the extent of overexpression and poor 
outcome in human patients (Slamon, Godolphin et al. 1989). 
Notably, over-expression of Neu induces profound RA-resistance (Tari, Lim et 
al. 2002).  The basis for this resistance is currently unknown.  However, previous 
observations demonstrated that injection of an adenovirus harboring CRABP-II into 
tumors that arise from MMTV-neu mice results in a significant delay in tumor 
development (Manor, Shmidt et al. 2003).  It was further shown that administration of 
RA in the presence of CRABP-II over-expression had no additional beneficial effects, 
and suggested that RA treatment in the absence of ectopic over-expression of CRABP-
II may have facilitated tumor growth.  Taken together, these observations raise the 
intriguing possibility that RA inhibits tumor growth in the presence of CRABP-II, 
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which delivers it to RAR, but facilitates tumor development in the absence of this 
binding protein.  Interestingly, such opposing effects of RA on cell growth was also 
noted in other studies.  While RA displays distinct anticarcinogenic activities when 
associated with RAR activation, it appears to promote rather than inhibit cell survival 
in some cell types and tissues (Verma, Conrad et al. 1982; Rodriguez-Tebar and 
Rohrer 1991; Henion and Weston 1994; Plum, Parada et al. 2001). For example, RA is 
critical for neural survival both in cultured cell models and in vivo. It was also shown 
that RA treatment can enhance keratinocyte proliferation (Verma, Conrad et al. 1982). 
The main goal of work described here was to delineate the molecular basis for these 
opposing activities of this hormone. 
 
 
1.7 Research Goals: 
 
The central hypothesis of this work is that RA activates two different nuclear 
receptors, RAR and PPARβ/δ, and that alternate activation of these receptor results in 
distinct cellular responses. We hypothesize further that the partioning of RA between 
its two receptors is regulated by two iLBPs, CRABP-II which delivers it to RAR and 
FABP5 which shuttles the hormone to PPARβ/δ.  To address these hypotheses, the 
work had two specific goals. 
 
1.  To investigate the roles of RA and its associated nuclear receptors and 
intracellular lipid binding proteins in regulation of cell growth.  
While activation of RAR by RA usually results in inhibition of cell growth, it 
has been reported that, in some circumstances, RA may operate through an RAR-
independent pathway to promote cell survival and enahnce proliferation.  Several cell 
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lines will be used to examine whether the RAR-independent, pro-proliferative 
activities of RA are mediated by PPARβ/δ.  Additional experiments will be carried out 
to investigate the possibility that CRABP-II and FABP5 regulate the partitioning of 
the hormone between the two receptors, and thus biological responses to RA. 
 
2.  To investigate the involvement of RA and its associated nuclear receptors and 
intracellular lipid binding proteins in tumor development in mammary cancer mouse 
models.  
To obtain insight into the involvement of the two RA receptors in tumor 
development in MMTV-neu mice, and to further examine the possibility that CRABP-
II and FABP5 regulate biological responses to RA, MMTV-neu mammary carcinoma 
mouse models that express varying expression ratios of the FABP5/CRABP-II will be 
generated.  Tumors that develop in these models will be analyzed as to transcriptional 
activities of RAR and PPARβ/δ, and as to characteristics of tumor development and 
histology. 
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CHAPTER TWO 
 
OPPOSING EFFECTS OF RETINOIC ACID ON CELL GROWTH RESULT 
FROM ALTERNATE ACTIVATION OF TWO DIFFERENT NUCLEAR 
RECEPTORS* 
 
 
 
 
 
 
 
 
 
 
 
*Reproduced with permission from: Schug, TT, Berry, DC, Shaw, NS, Travis, SN, 
and Noy, N. (2007) Opposing effects of retinoic acid on cell growth result from 
alternate activation of two different nuclear receptors. 
Cell 2007 May 18;129:723-733. Copyright 2007 Elservier Inc. 
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2.1 Summary 
 
Transcriptional activation of the nuclear receptor RAR by retinoic acid (RA) often 
leads to inhibition of cell growth.  However, in some tissues, RA promotes cell 
survival and hyperplasia, activities that are unlikely to be mediated by RAR.  Here we 
show that, in addition to functioning through RAR, RA activates the ‘orphan’ nuclear 
receptor PPARβ/δ, which, in turn, induces the expression of pro-survival genes.  
Partitioning of RA between the two receptors is regulated by the intracellular lipid-
binding proteins CRABP-II and FABP5.  These proteins specifically deliver RA from 
the cytosol to nuclear RAR and PPARβ/δ, respectively, thereby selectively enhancing 
the transcriptional activity of their cognate receptors.  Consequently, RA functions 
through RAR and is a pro-apoptotic agent in cells with high CRABP-II/FABP5 ratio, 
but it signals through PPARβ/δ and promotes survival in cells that highly express 
FABP5.  Opposing effects of RA on cell growth thus emanate from alternate 
activation of two different nuclear receptors. 
 
2.2 Introduction 
 
The vitamin A metabolite retinoic acid (RA) regulates multiple biological processes 
and plays key roles in embryonic development and in tissue remodeling in the adult.  
It is well established that many of the activities of RA are mediated by retinoic acid 
receptors (RARα, β, and γ), ligand-inducible transcription factors that are members of 
the superfamily of nuclear hormone receptors (Laudet and Gronemeyer, 2002).  
RARs associate with the retinoid X receptor (RXR) to form heterodimers that bind to 
regulatory regions of specific target genes and modulate transcriptional rates in 
response to their cognate ligands (Chambon, 1996; Mangelsdorf et al., 1994).  
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Transcriptional activation by RAR may trigger differentiation (Park et al., 1999; 
Rochette-Egly and Chambon, 2001), cell cycle arrest (Donato et al., 2007), and 
apoptosis (Altucci et al., 2001; Donato and Noy, 2005; Kitareewan et al., 2002), and 
thus often leads to inhibition of cell proliferation.  Accordingly, RA displays distinct 
anticarcinogenic activities and is currently used in or is being tested as a therapeutic 
agent in several human cancers (Soprano et al., 2004).   
However, in some tissues, RA appears to promote rather than inhibit cell 
survival.  For example, RA is critical for neuronal survival (Henion and Weston, 
1994; Jacobs et al., 2006; Plum et al., 2001; Rodriguez-Tebar and Rohrer, 1991), and 
it was reported that RA treatment can enhance skin tumor formation (Verma et al., 
1982).  RA is essential for normal keratinization in various epithelia (Wolbach and 
Howe, 1978), and topical administration of the hormone stimulates dermal repair and 
induces hyperproliferation of basal kertinocytes (Kang et al., 1995; Zouboulis, 2001).  
Interestingly, although RA plays critical roles in maintenance of skin integrity, mice 
lacking both RARα and RARγ as well as RARβ-null mice display normal 
keratinocyte proliferation (Chapellier et al., 2002).  These observations indicate that 
RARs are dispensable for keratinocyte renewal, and suggest that some RA activities 
in the skin are mediated by an RAR-independent pathway.   
We previously reported that RA binds with a high affinity to another nuclear 
receptor, namely PPARβ/δ, a member of a sub-class of receptors which also includes 
PPARα and PPARγ, and that, like RAR, functions as a heterodimer with RXR 
(Laudet and Gronemeyer, 2002).  Selective association of RA with PPARβ/δ was 
suggested by the observations that the Kd for RA-binding by this receptor is ~15 nM, 
about an order of magnitude stronger than that displayed by PPARα and 
PPARγ.  Correspondingly, in the context of a reporter gene construct, RA was found 
to efficiently activate PPARβ/δ but not PPARα or PPARγ (Shaw et al., 2003).  
Hence, an intriguing possibility is that, in some cells, RA may activate transcription 
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not only through RAR but also through PPARβ/δ.  It is noteworthy in regard to this 
that, in keratinocytes, PPARβ/δ induces differentiation and, importantly, displays 
pronounced anti-apoptotic activities mediated in part by direct transcriptional 
targeting of the PDK-1/Akt survival pathway (Di-Poi et al., 2002; Tan et al., 2004).  
Consequently, PPARβ/δ is central to maintenance of skin permeability-barrier 
integrity, and to keratinocyte survival during inflammation and wound healing (Di-
Poi et al., 2003; Icre et al., 2006).   
Ligands that activate RAR and the various PPAR isotypes also bind in cells to 
intracellular lipid binding proteins (iLBPs), a family of small proteins that share a 
remarkably similar 3-dimensional structure (Gutierrez-Gonzalez et al., 2002; 
Kleywegt et al., 1994; Veerkamp and Maatman, 1995), but bind lipophilic molecules 
with distinct selectivities.  Some members of this family, termed cellular retinoic acid 
binding proteins (CRABP-I and II), specifically associate with retinoic acid with 
subnanomolar affinities (Dong et al., 1999).  Other iLBPs, known as fatty acid 
binding proteins (FABPs), display broad selectivities and bind a variety of fatty acids 
and some fatty acid derivatives.  In fact, the spectrum of ligands that bind to FABPs is 
reminiscent of that of PPARs (Gutierrez-Gonzalez et al., 2002; Hanhoff et al., 2002; 
Norris and Spector, 2002; Widstrom et al., 2001).  The shared ligand selectivities of 
some iLBPs and some nuclear receptors suggest that specific members of the two 
classes of proteins may cooperate in regulating the biological activities of their 
common ligands.  Such a cooperation is also suggested by overlapping tissue 
expression profiles and by involvement in similar biological functions.    
Recent studies indeed demonstrated that three iLBPs, CRABP-II, FABP5 (K-
FABP, eFABP, mal1), and FABP4 (A-FABP, aP2), selectively cooperate with the 
nuclear receptors RARα, PPARβ/δ and PPARγ, respectively.  Specifically, these 
studies established that, upon association with particular ligands, these binding 
proteins translocate from the cytosol to the nucleus, that they engage in direct protein-
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protein interactions with their ‘cognate’ receptors, and that the resulting complex 
mediates ‘ligand-channeling’ from the binding protein to the receptor. Consequently, 
the binding proteins facilitate the ligation of the respective receptors and significantly 
augment their transcriptional activities (Budhu and Noy, 2002; Dong et al., 1999; 
Manor et al., 2003; Sessler and Noy, 2005; Tan et al., 2002).  Interestingly, although 
FABP4 and FABP5 bind multiple ligands, only particular compounds trigger their 
nuclear translocation (Tan et al., 2002). FABP4 moves into the nucleus in response to 
ligands that activate PPARγ but not upon treatment with PPARβ/δ ligands. In 
contrast, FABP5 mobilizes to the nucleus only in response to ligands that activate 
PPARβ/δ.   
Hence, available information suggests the possibility that, while RA inhibits 
cell- growth by signalling through RAR, the ‘non-traditional’ pro-proliferative 
activities of this hormone may be mediated by PPARβ/δ.  Work described in this 
manuscript was undertaken in order to examine this hypothesis, and to investigate the 
possibility that CRABP-II and FABP5 control the partitioning of RA between the two 
receptors. 
2.3 Experimental Procedures 
Reagents  CRABP-II antibodies were provided by Pierre Chambon (IGMCB, 
Strasbourg, France).  FABP5 antibodies were purchased from BioVender (Candler, 
NC).  Antibodies against full-length and cleaved PARP, and total and phospho-Akt 
(Thr308) were from Cell Signaling Technology.  Anti-mouse and anti-rabbit 
immunoglobulin antibodies conjugated to horseradish peroxidase were from 
Amersham (Arlington Heights, IL) and BioRad (Hercules, Ca), respectively.  
Anilinonaphtalene-8-sulphonic acid (ANS), RA, TNFα, and TRAIL were from 
Sigma Chemical Co. (St. Louis, MO).  4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-
tetramethyl-2-naphthalenyl)-1-propenyl]benzoic Acid (TTNPB) and GW0742 were 
purchased from Biomol International (Plymouth Meeting, PA) and Toronto Research 
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Diagnostics Inc. (Toronto, ON), respectively..  
Proteins.  Histidine-tagged CRABP-II and GST-tagged FABP5 were expressed in the 
E. coli strain BL21.  Bacteria were grown overnight at 25oC and protein expression 
was induced with 0.5 mM isopropyl-ß-D-thiogalactopyranoside (IPTG) overnight. 
Bacteria were pelleted and lysed in lysis buffer (20 mM Tris, pH 8.0, 0.5 mM NaCl, 
100 µM phenylmethylsulfonyl fluoride) containing lysozyme and DNAse I.  Mixtures 
were incubated (30 min., 37oC), centrifuged, and proteins purified by affinity 
chromatography, and dialyzed against lysis buffer.  
Cells. COS-7, HaCaT, NaF, and MCF-7 cells were maintained in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% charcoal-treated 
newborn bovine calf serum (Cocalico Biologicals Inc., Reamstown, Pa.).  COS-7 cells 
were transfected using Fugene (Roche Diagnostics Corporation).  Other cell lines 
were transfected using Superfect (Qiagen).   
Carcinogenesis studies in the MMTV-neu mice. A colony of the 
homozygous strain TgN(MMTVneu)202Mul mice was maintained on FVB/N 
background. All experiments were performed on virgin females.  Tumor development 
was monitored by palpation three times a week, and tumor sizes were recorded 
without knowledge of the applied treatment.  RA was administered by 90-day release 
15 mg pellets (Innovative Research of America, Sarasota, Florida) implanted 
subcutaneously on age 140 days.  Statistical analyses of tumor growth curves were 
performed on the natural log of tumor volumes in the two groups and compared with 
an unpaired t test using MINITAB software.  P value for comparison between 
survival curves was calculated using the Kaplan-Meier method. 
Transactivation assays.  Cells were cultured in 24-well plates and co-transfected 
with (PPRE)3-luciferase reporter vector
 (100 ng), a vector harboring the appropriate 
iLBP (in pCDNA 3.1, 200 ng), and pCH110, a β-galactosidase expression plasmid 
(50 ng).  In some experiments, an expression vector encoding RAR or PPARβ/δ (in 
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pSG5, 50 ng) was cotransfected. Transfections were carried out using Fugene (Roche 
Diagnostics Corporation) according to the protocol of the manufacturer. Twenty-four 
hours following transfection, medium was replaced by DMEM, and ligands were 
added (RA – in ethanol, other ligands - in dimethylsulfoxide).  Following 24 hr of 
treatment, cells were lysed and lysates assayed for luciferase activity (Luciferase 
assay system, Promega) which was corrected for β-galactosidase activity. 
Experiments were carried out in triplicates. 
Apoptosis was evaluated using the APOPercentage Apoptosis Assay kit (Biocolor 
Ltd. United Kingdom).  1x106 cells were suspended in 1 ml medium and dispensed 
into 96-well microplates.  Cells were grown overnight, treated with appropriate ligand 
(2 hr.) and apoptosis induced with TNFα or TRAIL overnight.  Medium was replaced 
with medium containing APOPercentage Dye Label.  The APOP% Dye Release 
Reagent was added and a microplate colorimeter was used to measure cell-bound dye 
recovered in solution. Apoptotic index was measured at λ - 595 nm. 
Binding assays were carried out by fluorescence titrations using a Fluorolog 2 DMIB 
spectrofluorometer (SPEX Instruments, Edison, N.J.).  FABP5 was bacterially 
expressed and purified and the equilibrium dissociation constants (Kd) that 
characterize its interactions with RA and GW0742 were measured by fluorescence 
competition assays. The method entails two steps (Lin et al., 1999).  In the first step, 
Kd for the association of the protein with the fluorescent fatty acid probe ANS was 
measured.  Protein (1 µM) was titrated with ANS from a concentrated solution in 
ethanol.  Ligand binding was monitored by following the increase in the fluorescence 
of the ligand upon binding to the protein (λex-370 nm; λem-475 nm).  Titration curves 
were analyzed (Norris and Li, 1998) to yield the number of binding sites and Kd.  
Kds for binding of non-fluorescent ligands were then measured by monitoring their 
ability to compete with fluorescent probes for binding.  The protein was pre-
complexed with ANS at 1:1 molar ratio and titrated with RA or GW0742 whose 
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binding was reflected by a decrease in probe fluorescence.  Kds were extracted from 
the EC50 of the competition curve and the measured Kd for the probe.  Analyses 
were carried out using Origin 7.5 software (MicroCal Software Inc., Northampton, 
Mass.).   
Quantitative real-time PCR (Q-PCR).  RNA was extracted and cDNA generated 
using Gene Amp RNA PCR (Applied Biosystems, Foster City, CA). Q-PCR analyses 
for PDK-1 were conducted using TaqMan chemistry and Assays on Demand probes 
(Applied Biosystems, PDK1 - Hs00176884_m1, ADRP - Hs00765634_ml, FIAF -   
Hs00211522_ml), Cyp26a – Hs01075671_g1, BTG2 – Hs00198887_m1, cyclin D1 0 
Hs00277039-m1.  18S ribosomal RNA (4319413E-0312010) was used as a loading 
control. Analyses were carried out using the relative standard curve method (Applied 
Biosystems Technical Bulletin no. 2). 
Confocal fluorescence microscopy.  COS-7 cells were plated in 35 mm glass bottom 
microwell dishes (Mattek) in DMEM containing 5% charcoal-treated FBS (75,000 
cells per plate), grown for 12 hr. and transfected using Fugene (Roche) with an 
expression vector harboring GFP-tagged FABP5 ( EGFP, 250 ng DNA per plate).  
Following a 48 hr incubation, medium was replaced with serum-free DMEM, and live 
cells were imaged using a Leica TCS SP2 confocal microscope equipped with a 40x 
oil immersion lens. After imaging, cells were treated with ligands (1 µM), incubated 
at 37°C for 30 min and imaged again. An average of  40 cells were analyzed using 
ImageJ (National Institute of Health). 
Chromatin immunoprecipitation assays.  Nearly confluent HaCat cells were treated 
with vehicle or RA (1 µM, 45 min.). Proteins were cross-linked to DNA (1% 
formaldehyde, 10 min.).  Cells were washed with PBS, scraped, collected, lysed (1% 
SDS, 10 mM EDTA, 50 mM Tris, pH 7.9, 1 mM DTT, and protease inhibitors 
(Roche), and incubated on ice (45 min.).  Samples were sonicated three times, and 
chromatin precleared with protein A beads (2 hr.).  Antibodies against PPARβ/δ (H-
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74, Santa Cruz) or pre-immune rabbit IgG were added and mixtures incubated 
overnight at 4°C.  Protein A beads were added and mixed (2 hr., 4°C). Beads were 
washed twice with low-salt buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% Nonidet 
P-40, 1 mM EDTA, 50 mM Tris-HCl), twice with high salt buffer (low salt buffer + 
500 mM NaCl), and twice with Tris-EDTA buffer. Cross-link was then reversed (100 
mM NaHCO3, 1% SDS, overnight 65°C), proteins digested with proteinase K (1 hr.), 
and DNA purified (nucleotide extraction kit, Qiagen). The PPRE containing regions 
of ADRP (http://www.nuclear-receptor.com/content/pdf/1478-1336-3-3.pdf) 
and FIAF (http://www.jbc.org/cgi/reprint/279/33/34411) were amplified by PCR 
using the following primers.  ADRP: 5'-CCTCTGCTTCACAGGCAAATA -3' 
(forward) and 5'-TGCATCAGAAGACTCTCGCCCTTT-3' (reverse); FIAF: 5'-
AATCATGGAAGCCACACTGGTGGT -3' (forward) and 5'-
CCCTACTTTCCTCCCATCCAGTAA-3' (reverse). Primers specific for a region 6-
kb upstream of the GAPDH promoter,  5'-TCACGCCTGTAATCCCAGCACTTT -3' 
(forward) and, 5'-TGATTTCGGCTCACTACAACCTCC-3' (reverse), were used as a 
negative control.  
 
2.4 Results 
 
RA facilitates tumor growth in the MMTV-neu transgenic mammary 
cancer model.  In keratinocytes, RA exerts pro-proliferative activities that appear to 
be mediated by a pathway other than activation of RAR (Chapellier et al., 2002).  In 
search for an additional model that will allow for exploring the mechanisms that 
underlie ‘non-traditional’ activities of RA, we considered the transgenic mammary 
cancer mouse model TgN(MMTVneu)202Mul (Akagi et al., 1997; Guy et al., 1992).   
The oncogenic hallmark of this model is a mammary-specific amplification of 
the growth factor receptor c-erb-B2/neu, which is often amplified in primary human 
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breast cancers (King et al., 1985).  This model, in which 100% of female mice 
develop mammary adenocarcinomas (Muller et al., 1988), was chosen because it has 
been reported that over-expression of neu in mammary carcinoma cells leads to RA-
resistance, suggesting down-regulation of RAR signalling (Tari et al., 2002).  To  
examine the effects of RA on tumor development, the rate of tumor growth was 
 
  
 
 
Figure 2.1.  RA facilitates tumor growth in MMTV-neu mice.  Tumor growth was 
monitored in untreated female MMTV-neu mice and in mice subjected to systemic 
RA as of age 140 d.  A. Sizes of tumors were measured with calipers with a start 
point (day 0) of tumor volume = 0.065 cm3.   Volumes of tumors in untreated (closed 
symbols) and RA-treated (open symbols) on day 20 were 1.09±0.22 cm3 vs. 
1.87±0.25 cm3 (mean±SEM; n=12 in each group, P = 0.04).  B. Mice were treated as 
described in a., and survival, defined as the age in which tumor volume reached 0.524 
cm3, was assessed.  Median survivals were 240 and 205 days for untreated mice (open 
symbols) and RA-treated mice (closed symbols, n=12 in each group, P = 0.001).  
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studied in untreated mice and in mice systemically treated with RA as of age 140 
days.  Measurements were initiated when tumors reached a volume of 0.065 cm3.  
The data (Fig. 2.1A) showed that RA treatment dramatically facilitated tumors 
formation with mean tumor volume on day 20 of 1.09±0.22 cm3 in untreated mice,  
and 1.87±0.25 cm3 in the RA-treated group (mean±S.E.M., n = 12 in each group, P = 
0.04).  Assessment of mouse survival, defined as the time when tumor volume 
reached 0.524 cm3 (Fig. 2.1B), indicated that, although all mice eventually developed 
tumors of that size,  the median survival of RA-treated vs untreated mice was 205 vs 
240 days (P = 0.001).  Hence, RA exerts pro-proliferative activities in tumors that 
arise in MMTVneu mice.   
Subsequent experiments thus utilized two cell lines in which RA displays 
‘non-traditional’ activities, leading to cell survival and growth: HaCaT keratinocyte 
cells, and NaF cells, derived from tumors that arise in MMTVneu mice.  For 
comparison, we employed MCF-7 mammary carcinoma cells, in which RA is known 
to function through RAR and to inhibit cell proliferation (Donato and Noy, 2005; 
Donato et al., 2007; Mangiarotti et al., 1998; Toma et al., 1998). 
 
In HaCaT keratinocytes, RA activates PPARβ /δ  in parallel to activation of 
RAR.  The ability of RA to activate PPARβ/δ in the human keratinocyte cell line 
HaCaT was examined.  Transcriptional activation assays conducted using a luciferase 
reporter driven by a consensus PPAR response element (PPRE) showed that the 
synthetic PPARβ/δ-selective ligand GW0742, but not the RAR-selective ligand 4-
[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic 
acid (TTNPB), induced transcription of the reporter (Fig. 2.2A).  These observations 
attest to the expression and functionality of PPARβ/δ in these cells and demonstrate 
specificity of reporter response.  
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Figure 2.S1.  PPARβ /δ  associates with the PPRE of the ADRP and FIAF  genes 
in live HaCaT cells.   Chromatin immunoprecipitation assays were conducted in 
HaCaT cells using pre-immune IgG or antibodies against PPARβ/δ.  The regions 
containing the PPRE of the ADRP and FIAF genes were amplified using appropriate 
primers (see Experimental Procedures).  A 220 bp region 6-kb upstream from the strat 
site of GAPDH was used as a negative control.  
 
RA also enhanced the expression of the PPRE-driven reporter and did so in a dose-
responsive manner (Fig. 2.2B).  The response was markedly suppressed when the 
expression of PPARβ/δ in the cells was decreased by about 80% by siRNA 
methodology (Fig. 2.2B), indicating that the ability of RA to induce reporter 
expression was indeed mediated by this receptor and not by RAR.   
We then set out to examine the ability of RA to induce the expression of endogenous 
PPARβ/δ.target genes in HaCaT cells.  One of these, PDK-1, was previously shown 
to comprise a direct PPARβ/δ target in HaCaT cells (Di-Poi et al., 2002).  Two other 
genes, fasting induced adipose factor (FIAF) (Kersten et al., 2000) and adipose 
differentiation-related protein (ADRP) (Schmuth et al., 2004), were reported to be 
targeted by PPARβ/δ in other cells.  Chromatin immunoprecipitation assays 
demonstrated that PPARβ/δ associates with the PPAR response elements of both 
FIAF and ADRP in HaCaT cells (Fig. 2.S1), verifying that both are direct targets for  
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Figure 2.2.  In HaCaT cells, RA activates both PPARβ /δ  and RAR.  a. and b. A.  
Cells were  treated with vehicle or GW0742 (GW) or TTNPB (T, 1 µM).  B. Cells 
were cotransfected with either control siRNA or siRNA for PPARβ/δ, and than 
treated with RA at the denoted concentrations. C. HaCaT cells were treated with 
denoted ligands. Levels of mRNA of the PPARβ/δ target genes FIAF, ADRP, and 
PDK-1 were analyzed by Q-PCR and normalized to 18s mRNA. Data are 
mean±SEM, n=3.  D. HaCaT cells were transfected with control siRNA or PPARβ/δ 
siRNA (24 hr.), and then treated with the denoted ligands (0.1 µM, 4 hr) and RNA 
extracted. E.  Cells were treated with denoted ligands (0.1 µM, 12 hr) and lysed.  Thr-
307-phospho-Akt, total Akt, and β-tubulin were assessed by immunoblots. F. Cells 
were treated with RA (15 hr), lysed, and luciferase activity measured and corrected 
for β-galactosidase activity. G.  Cells were treated with the denoted ligands and 
expression of mRNA of the RAR target gene Cyp26a analyzed by Q-PCR.  
this receptor in the context of these cells.   
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The PPARβ/δ ligand GW0742 as well RA also enhanced the expression of the PPRE-
driven reporter and did so in a dose-responsive manner (Fig. 2.2B).  The response 
was markedly suppressed when the expression of PPARβ/δ in the cells was decreased 
by about 80% by siRNA methodology (Fig. 2.2B), indicating that the ability of RA to 
induce reporter expression was indeed mediated by this receptor and not by RAR.   
We then set out to examine the ability of RA to induce the expression of 
endogenous PPARβ/δ.target genes in HaCaT cells.  One of these, PDK-1, was 
previously shown to comprise a direct PPARβ/δ target in HaCaT cells (Di-Poi et al., 
2002).  Two other genes, fasting induced adipose factor (FIAF) (Kersten et al., 2000) 
and adipose differentiation-related protein (ADRP) (Schmuth et al., 2004), were 
reported to be targeted by PPARβ/δ in other cells.  Chromatin immunoprecipitation 
assays demonstrated that PPARβ/δ associates with the PPAR response elements of 
both FIAF and ADRP in HaCaT cells (Fig. 2.S1), verifying that both are direct targets 
for this receptor in the context of these cells.  The PPARβ/δ ligand GW0742 as well 
as RA upregulated the expression of mRNA for all three of these endogenous 
PPARβ/δ target genes (Fig. 2.2C).  The observations that the RAR-ligand TTNPB 
had little effect on the expression of these genes further confirm that RAR is not 
involved in this activity of RA.  As a control, cells were treated with 9-cis-RA 
(9cRA), a ligand that activates RXR, the obligatory heterodimerization partner for 
both RAR and PPARs (Levin et al., 1992).  This ligand induced a modest response, 
which likely emanated from activation of the RXR moiety of the RXR-
PPARβ/δ heterodimer.  The small magnitude of the response indicates that the 
induction of ADRP and FIAF by RA is not a result of conversion of RA to its 9-cis 
isomer within the cells.  Further support for the conclusion that upregulation of these 
genes by RA is mediated by PPARβ/δ was provided by the observations that an 80% 
decrease in the expression of this receptor significantly hampered the induction of 
ADRP by both GW0747 and RA (Fig. 2.2D).   
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Notably, one of the PPARβ/δ targets found to be induced by RA, PDK-1, is 
an important component of the anti-apoptotic activities of this receptor in 
keratinocytes, where induction of this kinase leads to phosphorylation and activation 
of the downstream PDK-1-target survival factor Akt (Di-Poi et al., 2002).  The effects 
of RA or GW0742 on the phosphorylation level of Akt were thus examined.  
Treatment with either of these ligands, but not with TTNPB or 9cRA, significantly 
increased the phosphorylation level of Akt (Fig. 2.2E).   
In addition to activating PPARβ/δ, RA also upregulated the expression of a 
reporter gene construct driven by an RAR response element (Fig. 2.2F), and it 
efficiently upregulated the expression of mRNA for CYP26a, a known direct RAR 
target gene (Loudig et al., 2000) (Fig. 2.2G).  Hence, in HaCaT cells, RA treatment 
results in parallel activation of both RAR and PPARβ/δ.   
 
FABP5 translocates into the nucleus in response to RA, and it enhances RA-
induced, PPARβ /δ-mediated transcriptional activation.  The observations that RA 
can activate both RAR and PPARβ/δ raise the question of the factors that regulate the 
dual activity of this hormone.  We previously showed that the iLBPs CRABP-II and 
FABP5 mobilize to the nucleus in response to ligands that activate RAR and 
PPARβ/δ, respectively, and that they bind to their cognate receptors to form a 
complex through which the ligand is directly ‘channeled’ to the receptor.  
Consequently, CRABP-II enhances the transcriptional activity of RAR, while FABP5 
facilitates the activation of PPARβ/δ (Budhu and Noy, 2002; Donato and Noy, 2005; 
Dong et al., 1999; Manor et al., 2003; Tan et al., 2002).  The observations that RA 
serves as a ligand for PPARβ/δ thus raise the possibility that RA may be delivered to 
this receptor by FABP5.  A fluorescence-based binding assay (Fig. 2.3A) 
demonstrated that GW0742 and RA bind to FABP5 with Kds of 42.3±4.5 nM, and 
34.8±6.6 nM, respectively (mean±SD, n=3), in good agreement with binding  
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Figure 2.3.  FABP5 binds RA, translocates to the nucleus in response to this 
ligand, and enhances RA-induced activation of PPARβ /δ.  A. FABP5 was titrated 
with the fluorescence probe ANS.  Titrations curves (left panel, filled squares) were 
corrected for linear non-specific fluorescence (solid line at end of titration curve), and 
corrected data (filled circles) analyzed to yield a Kd of 57±7.3 nM (mean±SD, n=3).  
Kds for the association of FABP5 with RA (middle panel) and with GW0742 (right 
panel) were determined by fluorescence competition titrations.  B. COS-7 cells were 
transfected with an expression vector harboring GFP-FABP5 and imaged.  Images 
were acquired from live cells before and after a 30 min. treatment with RA (1 µM).  
Right panel: quantitation of nuclear/cytoplsmic partitioning of FABP5 in cells treated 
with denoted ligands.  C. HaCaT cells were treated with denoted RA or with stearic 
acid (1 µM, 30 min.).  Nuclei were separated from cytosol by subcellular 
fractionation (Calbiochem ProtoExtract Subcellular Proteome Extraction kit) and 
anlyzed for the presence of FABP5 by immunoblots.  Efficiency of fractionation was 
validated by immunoblotting for the cytosolic marker GAPDH, and the nuclear 
marker histone 1.  D. Transactivation assays were carried out in COS-7 cells 
cotransfected with a luciferase reporter driven by a PPRE and an expression vector 
for PPARβ/δ (left panel) or with an RARE-driven reporter together with an 
expression vector for RARα (right panel). E.  HaCaT cells were not transfected, or 
transfected with either control siRNA or a construct harboring FABP5 siRNA (24 
hr.).  The ability of denoted ligands to induce ADRP expression was monitored by Q-
PCR and normalized to 18s mRNA. Data are mean±SEM, n=3.   
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affinities of this protein towards other ligands (Tan et al., 2002).  The subcellular 
localization of FABP5 was then examined.  COS-7 cells were transfected with 
FABP5 fused to green fluorescence protein (GFP), and confocal fluorescence 
microscopy was used to image GFP-FABP5 in live cells treated with 
various ligands (Fig. 2.3B).  Similarly to the behavior of GFP when transfected alone, 
GFP-FABP5 in untreated cells distributed between the cytoplasm and the nucleus, 
most likely reflecting that over-expression of the protein leads to leakage into the 
nucleus even in the absence of a specific nuclear localization signal (data not shown 
and (Sessler and Noy, 2005).  Treatment of cells with stearic acid, a long chain fatty 
acid that binds FABP5 but does not activate it, did not affect the subcellular 
distribution of the protein.  In contrast, treatment with either GW0742 or RA resulted 
in a distinct shift of the protein into the nucleus (Fig. 2.3B).  To monitor the effects of 
ligands on the localization of endogenous FABP5 in HaCaT cells, cells were treated 
with vehicle, RA, or stearate, subjected to subcellular fractionation, and the presence 
of FABP5 in cytosol and in nuclei examined by immunoblots (Fig. 2.3C).  The data 
demonstrated that endogenous FABP5 in HaCaT cells is predominantly cytosolic in 
the absence of ligand, and that it accumulates in the nucleus in response to RA, but 
not upon treatment with stearic acid.  Hence, like known PPARβ/δ-ligands, RA 
activates the nuclear localization of FABP5.  
The effects of FABP5 on the ability of RA to activate PPARβ/δ were 
examined by transactivation assay using COS-7 cells which express very low level of 
either FABP5 or CRABP-II.  Cells were co-transfected with a luciferase reporter 
construct driven by a PPRE, an expression vector for PPARβ/δ, and a vector 
harboring cDNA for either FABP5 or CRABP-II.  Cells were then treated with RA, 
and the expression of the reporter monitored (Fig. 2.3D, left panel).  RA enhanced the 
expression of the PPRE-driven reporter in a dose-responsive manner.  While 
expression of CRABP-II did not affect the activity, FABP5 significantly enhanced 
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RA-induced, PPARβ/δ-mediated transactivation.  To investigate the effect of the 
binding proteins on RA-induced activation of RAR, cells were transfected with a 
luciferase reporter under the control of an RAR response element (RARE), an 
expression construct for RARα, and a vector harboring cDNA for either FABP5 or 
CRABP-II.  In agreement with previous reports, CRABP-II augmented RA-induced 
transactivation of RAR.  On the other hand, FABP5 had little effect on this activity 
(Fig. 2.3D, right pane).  Cells in which the receptors were not ectopically expressed 
displayed qualitatively similar behaviour but the magnitudes of the ligand-induced 
responses were significantly smaller (not shown).   
The involvement of FABP5 in RA-induced activation of PPARβ/δ was further 
investigated by examining the effect of decreasing the expression level of this binding 
protein on the ability of RA to activate the receptor in HaCaT cells.  Cells were 
transfected with FABP5 siRNA, resulting in an about 80% decrease in  the level of 
the protein, and induction of the PPARβ/δ target gene ADRP was monitored (Fig. 
2.3E).  Decreasing the expression of FABP5 markedly attenuated the ability of both 
GW0742 and RA to upregulate the expression of the ADRP, further substantiating 
that the presence of FABP5 is necessary for efficient activation of PPARβ/δ by its 
ligands, including RA. 
 
Decreasing the FABP5/CRABP-II ratio in HaCaT and NaF cells converts RA 
from a survival factor to a pro-apoptotic agent.  The observations that RA is 
delivered to RAR by CRABP-II, and is shuttled to PPARβ/δ by FABP5 suggest that 
differential expression profiles of these iLBPs may regulate the partitioning of RA 
between the two receptors in different cells.  The levels of the two binding proteins 
were thus examined in several tissues and cells.  Of special interest are mammary 
tumors that arise in the transgenic mouse cancer model MMTVneu.  RA treatment of 
MMTVneu mice facilitates mammary tumor development (Fig. 2.1).  On the other 
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hand, it was previously reported that ectopic expression of CRABP-II in these tumors 
induces carcinoma cell apoptosis and suppresses tumor growth (Manor et al., 2003), 
indicating that, under these conditions, RA exerts growth-inhibitory activities.  
Comparison between the expression levels of CRABP-II and FABP5 in tumors that 
arise in MMTVneu mice and in adjacent normal mammary tissue revealed that 
CRABP-II expression is markedly decreased, while the level of FABP5 is 
significantly higher in the tumors (Fig. 2.4A).  Hence, tumor development in 
MMTVneu mice is accompanied by a dramatic decrease in the CRABP-II/FABP5 
ratio.  Corresponding to this expression profile in vivo, NaF cells, a cell line derived 
from MMTVneu tumors, display a high level of FABP5 and minimal expression of 
CRABP-II (Fig. 2.4B).  Similarly, HaCaT cells, in which RA can function through 
PPARβ/δ, express a high level of FABP5 and an undetectable CRABP-II content  
(Fig. 2.4B).  In contrast, the mammary carcinoma MCF-7 cells, in which RA activates 
RAR to inhibit cell growth (Donato and Noy, 2005; Donato et al., 2007; Mangiarotti 
et al., 1998; Toma et al., 1998), and F9 teratocarcinoma cells, which differentiate into 
primitive endoderm in response to RA-induced, RAR-mediated signalling (Rochette-
Egly and Chambon, 2001; Strickland and Mahdavi, 1978; Strickland et al., 1980), 
express a markedly higher CRABP-II/FABP5 ratio (Fig. 2.4B).   
The effect of reversing the CRABP-II/FABP5 ratio in HaCaT cells on the 
ability of RA to activate PPARβ/δ was then examined.  Cells were transfected with 
either an expression vector for CRABP-II, or with a construct harboring FABP5 
siRNA (Fig. 2.4C),  treated with RA or GW0742, and induction of the 
PPARβ/δ target gene PDK-1 was monitored (Fig. 2.4D).  Over-expression of 
CRABP-II had little effect on GW0742-induced expression of PDK-1 mRNA, 
indicating that this protein does not directly affect PPARβ/δ activity.  Either over-
expression of CRABP-II or under-expression of FABP5 abolished the ability of RA 
to induce PDK-1 expression.  Additionally, in accordance with the observations that  
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Figure 2.4.  In HaCaT cells, decreasing the FABP5/CRABP-II ratio diverts RA 
away from PPARβ /δ .  A.  Expression of CRABP-II and FABP5 in mammary 
tumors that arise in MMTVneu mice and in adjacent normal mammary tissue 
estimated by immunoblots.  B.  Expression levels of CRABP-II and FABP5 in 
HaCaT, NaF, MCF-7, and F9 cells were estimated by immunoblots. C.  HaCaT cells 
were transfected with an expression vector for CRABP-II or with a vector harboring 
FABP5 siRNA.  Effectiveness of transfection in modulating the proteins’ expression 
levels was monitored by immunoblotting.  D.  Parental HaCaT cells and HaCaT cells 
over-expressing CRABP-II or under-expressing FABP5 were treated with denoted 
ligands (1 µM, 4 hr) and expression of PDK-1 mRNA was measured by Q- PCR.  
Data are mean±SEM, n=3.  
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GW0742 tightly binds to FABP5 and mobilizes it to the nucleus (Fig. 2.3), 
decreasing 
FABP5 expression augmented the transcriptional activity of this ligand.  The 
data thus show that increasing the CRABP-II/FABP5 ratio in HaCaT cells diverts RA 
away from PPARβ/δ.  The involvement of FABP5 in induction of PDK-1 by both RA 
and GW0742 also supports the notion that this binding protein mediates the nuclear 
targeting of both of these PPARβ/δ ligands. 
Upregulation of PDK-1 expression upon activation of PPARβ/δ by RA in 
HaCaT cells results in the phosphorylation and thus the activation of the survival 
factor Akt (Fig. 2.2E).  It can thus be predicted that RA treatment will protect these 
cells against apoptosis.  To examine this notion, HaCaT cells were treated with the 
apoptosis inducer tumor necrosis factor α (TNFα), and the effects of RA, the 
PPARβ/δ ligand GW0742, and the RAR ligand TTNPB on TNFα-induced apoptosis 
were examined.  To this end, we monitored the ability of TNFα to trigger the 
cleavage of poly(ADP-ribose) polymerases (PARP), one of the earliest proteins 
targeted for a specific cleavage during apoptosis (Fig. 2.5A, 5B).  TNFα treatment 
significantly enhanced PARP cleavage, demonstrating the efficacy of the cytokine as 
an apoptosis-inducing agent in these cells.  In agreement with a role for PPARβ/δ in 
enabling keratinocyte survival during inflammation (Di-Poi et al., 2002; Tan et al., 
2001), activation of the receptor by GW0742 inhibited TNFα-induced apoptosis.  
Similarly to GW0742, RA protected the cells from TNFα-induced apoptosis.  In 
contrast, the RAR-ligand TTNPB induced apoptosis when administered alone, and 
augmented TNFα-induced PARP cleavage, demonstrating that RAR displays pro-
apoptotic activities in these cells.  Hence, in HaCaT cells, RA inhibits apoptosis like a 
bona-fide PPARβ/δ ligand, an activity that diametrically contrasts with the pro-
apoptotic activities of RAR. 
The hypothesis that CRABP-II and FABP5 control the partitioning of RA  
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Figure 2.5.  In HaCaT and NaF cells decreasing the FABP5/CRABP-II ratio 
converts RA from an anti-apoptotic to a pro-apoptotic agent.  A.  HaCaT cells 
were treated with denoted ligands (2 µM, 2 hr) prior to addition of TNFα (20 ng/ml, 
14 hr.).  Cells were lysed and the level of cleaved PARP assessed by immunoblots.  A 
representative experiment is shown.  B. Quantitation of data described in panel a.  
Band intensities were normalized to the loading control GAPDH.  Data are 
mean±SEM, n=3.   C. and D.  Parental HaCaT (C.) or NaF (D.) cells and 
corresponding cells over-expressing CRABP-II or under-expressing FABP5 were 
treated with denoted ligands (1 µM, 16 hr.), or pretreated with ligands for 2 hr. prior 
to addition of TNFα (20 ng/ml, 14 hr., solid bars).  Apoptosis was evaluated using the 
APOPercentage Apoptosis Assay kit.  Data are mean±SEM, n=3.   
 
between RAR and PPARβ/δ and the biological activities of this hormone, was further 
investigated by examining the outcome of changing the CRABP-II/FABP5 ratio 
on the ability of RA to modulate TNFα-induced apoptosis.  In these experiments, 
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apoptosis was followed by monitoring the transfer of phosphatidylserine to the outer 
leaflet of the cell membrane, a process linked to the execution phase of apoptosis.  In 
agreement with observations obtained by monitoring PARP cleavage as a ‘readout’ 
for apoptosis, treatment of HaCaT cells with GW0742 or RA had little effect, while 
the RAR-ligand TTNPB increased the fraction of apoptotic cells (Fig. 2.5C).  Also in 
agreement, TNFα efficiently induced apoptosis, both GW0742 and RA inhibited, and 
TTNPB enhanced the response.  Strikingly, over-expression of CRABP-II not only 
abolished the protective activity of RA, but converted it into an agent which, similarly 
to TTNPB, enhanced TNFα-induced apoptosis.  Reduced expression of FABP5 also 
negated the anti-apoptotic activity of RA.  The observation that the decreased 
expression of FABP5 did not quite lead to an enhancement of the apoptotic response 
likely reflects that transfection of FABP5 siRNA reduced but did not completely 
inhibit the expression of the protein (Fig. 2.4C).  Similar effects were observed in 
NaF cells, derived from mammary tumors of the MMTVneu mouse model; RA 
‘rescued’ NaF cells from TNFα-induced apoptosis, and either over-expression of 
CRABP-II or under-expression of FABP5 abolished the protective activity of RA and 
enhanced the apoptotic response (Fig. 2.5D).   
 
In MCF-7 cells, increasing the FABP5/CRABP-II ratio converts RA from a pro-
apoptotic to an anti-apoptotic agent.  Unlike HaCaT and NaF cells, the mammary 
carcinoma MCF-7 cells display a high CRABP-II/FABP5 ratio (Fig. 2.4B).  To 
reverse this ratio, cell were co-transfected with an expression vector for FABP5 and a 
construct harboring CRABP-II siRNA (Fig. 2.6A).  The ensuing concomitant increase 
in FABP5 and decrease in CRABP-II levels did not affect the expression of either 
RAR or PPARβ/δ (Fig. 2.S2).  Nevertheless, the reversal hampered the ability of RA 
to upregulate the expression of the cell cycle regulator BTG2, a gene that was recently 
shown to comprise a direct target for RAR and to be involved in mediating RA-
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induced cell cycle arrest in MCF-7 cells (Donato et al., 2007)(Fig. 2.6B).  
Correspondingly, the reversal abolished the ability of RA to down-regulate the 
expression of cyclin D1, a known down-stream target for BTG2 (Guardavaccaro et 
al., 2000; Kawakubo et al., 2006; Kawakubo et al., 2004; Lim et al., 1989) (Fig. 
2.6C).  Reversing the FABP5/CRABP-II also inhibited RA-induced induction of the 
RAR target cyp26a (Fig. 6D).  Remarkably, while RA had little effect on the level of 
the direct PPARβ/δ target gene PDK-1 in parental MCF-7 cells, the ligand 
significantly upregulated the expression of this survival factor upon the reversal of the 
ratio of the binding proteins (Fig. 2.6E).  Hence, increasing the FABP5/CRABP-II 
ratio in MCF-7 cells directed RA away from RAR and towards PPARβ/δ.   
 
 
 
 
 
 
 
Figure 2.S2.  Switching the FABP5/CRABP-II ratio in MCF-7 cells does not 
affect the expression of either RAR or PPARβ /δ .   MCF-7 cells were mock 
transfected or co-transfected with an expression vector for FABP5 and with CRABP-
II siRNA, and treated as denoted.  a.  The level of all RAR isotypes was assessed by 
immunoblots using pan-RAR antibodies (Santa Cruz Biotechnology).  b.  The levels 
of mRNA for PPARβ/δ were measured by Q-PCR using TaqMan chemistry and 
Assays on Demand probes (Applied Biosystems, Hs00602622_m1), and normalized 
to 18s. 
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Considering the disparate nature of the RAR and PPARβ/δ target genes, the 
observations suggest that the reversal of the CRABP-II/FABP5 ratio hampered 
growth-inhibitory activities and triggered a survival response. 
To further examine the consequences of the ‘switch’ in binding protein 
profile, parental MCF-7 cells and cells in which the CRABP-II/FABP5 ratio was 
reversed were treated with the apoptosis-inducing agent tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL).  Apoptosis was monitored by following PARP 
cleavage (Fig. 2.6F) as well as by monitoring transfer of phosphatidylserine to the 
outer leaflet of the cell membrane (Fig. 2.6G).  Transfection of constructs encoding 
FABP5 and CRABP-II siRNA  resulted in PARP cleavage even in the absence of 
TRAIL.  The effect is likely to stem from a degree of apoptosis induced by the forced 
over-expression, and was not observed upon monitoring later apoptosis events, 
represented by phosphatidylserine membrane “flip”.  Treatment with TRAIL induced 
marked apoptosis as judged by both PARP cleavage and by plasma membrane events.  
Addition of TRAIL in conjunction with RA had little effect (PARP cleavage) or 
somewhat enhanced apoptosis (phosphatidylserine translocation).  Remarkably, both 
‘read-outs’ clearly demonstrated that, in cells in which the CRABP-II/FABP5 ratio 
was reversed, RA treatment markedly inhibited TRAIL-induced apoptosis.  Hence, 
increasing the FABP5/CRABP-II ratio in MCF-7 cells results in conversion of RA 
from a growth-inhibitory to a pro-survival factor 
 
2.5 Discussion 
 
RA activates the nuclear receptor RAR and, in many embryonic and adult tissues, the 
biological activities of this hormone can be traced to induction of expression of RAR 
target genes.  However, in some tissues, such as skin, important functions of RA 
appear to be mediated by an RAR-independent pathway, the nature of which  
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Figure 2.6.  In MCF-7 cells, increasing the FABP5/CRABP-II ratio converts RA 
from a pro-apoptotic agent to a survival factor.  A. MCF-7 cells were co-
transfected with an expression vector for FABP5 together with CRABP-II siRNA, 
and protein expression levels monitored by immunoblotting.  B.-E.  MCF-7 cells 
were mock transfected or co-transfected with an expression vector for FABP5 and 
with CRABP-II siRNA, and treated with RA.  Levels of mRNA for BTG2 (B.), cyclin 
D1 (C.), cyp26a (D.), and PDK-1 (E.) were measured by Q-PCR.  F. and G.  MCF-7 
cells were mock transfected or co-tranfected with an expression vector for FABP5 
and with CRABP-II siRNA.  Cells were treated with TRAIL (4 ng/ml), or RA (0.1 
µM), or both, and apoptosis was assessed  (F.) and by monitoring transfer of 
phosphatidylserine using the APOPercentage Apoptosis Assay kit (G.).   
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Figure 2.7.  A model outlining the dual transcriptional activity of RA.  CRABP-
II and FABP5 target RA to RAR and PPARβ /δ, respectively.  In cells that 
express a high CRABP-II/FABP5 ratio, RA is ‘channeled’ to RAR, often resulting in 
growth inhibition.  Conversely, in the presence of a low CRABP-II/FABP5 
expression ratio, RA is targeted to PPARβ/δ, thereby upregulating survival pathways. 
 
remained unclear.  The observations presented here indicate that, in addition to 
activating RAR, RA can also activate the nuclear receptor PPARβ/δ, and thus that the 
repertoire of genes and cellular responses that can be controlled by this hormone 
include both RAR and PPARβ/δ-targets.  The data show further that partitioning of 
RA between its two receptors is regulated by cognate iLBPs; CRABP-II delivers RA 
to RAR, while FABP5 shuttles the hormone to PPARβ/δ (Fig.2.7).  It should be noted 
that the binding affinity of the CRABP-II/RAR pathway for RA exceeds that of the 
FABP5/PPARβ/δ path.  The interactions of RA with both CRABP-II and RAR are 
characterized by Kds in the 0.1-0.2 nM range (Dong et al., 1999; Sussman and de 
Lera, 2005), while both FABP5 and PPARβ/δ associate with this compound at a Kd 
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of 10-50 nM ((Tan et al., 2002) and Fig. 3A).  It can thus be predicted that, in most 
cells, RA signalling through RAR will predominate, and that activation of PPARβ/δ 
will become apparent only in cells that exhibit a high FABP5/CRABP-II ratio.  This 
indeed appears to be the case.  In MCF-7 cells, which express a low FABP5/CRABP-
II ratio, RA activates RAR, while keratinocytes and NaF cells, which display a high 
FABP5/CRABP-II ratio, respond to RA by activation of PPARβ/δ.   
A high FABP5/CRABP-II ratio abolishes RA-triggered upregulation of RAR 
target genes that mediate important biological responses, such as cell cycle arrest 
(Fig. 2.6B, 2.6C).  It is worth noting however that cells that display such a ratio retain 
the ability to induce the expression of very efficient RAR targets, such as the RA-
degrading enzyme Cyp26a, albeit at a muted response (Fig. 2.2G and 2.6D).  Hence, 
critical functions of RA that are mediated by RAR, such as the ability to trigger its 
own degradation by upregulting the expression of cyp26 (White et al., 1996), can 
proceed in the background of the predominant action of RA-evoked 
PPARβ/δ signalling. 
The present work demonstrates that RA serves as a physiological ligand for 
PPARβ/δ under some but not all circumstances.  However, this receptor displays 
near-ubiquitous tissue expression (Kliewer et al., 1994), raising the question of the 
nature of the ligand(s) that activate it in tissues that do not support activation by RA.  
The ligand-binding pocket of PPARβ/δ is much larger than the pockets of other 
nuclear receptors (Xu et al., 1999).  It may thus accommodate multiple ligands, and it 
has been suggested that various long chain fatty acids and eicosanoids may serve as 
effective PPARβ/δ activators (Bucco et al., 1997).  Whether some of these ligands 
function as true physiological ligands for the receptor remains to be clarified, but the 
present work and the similar nature of ligands that bind to FABPs and PPARs 
(Hanhoff et al., 2002; Widstrom et al., 2001) raise the possibility that FABPs other 
than FABP5 may act to deliver ligands other than RA to PPARβ/δ, and thus that they 
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may regulate the functionality of distinct ligands in specific tissues.     
  When enabled, RA signalling through PPARβ/δ has profound functional 
consequences.  One consequence, explored here, is that such signalling evokes potent 
anti-apoptotic activities that overcome the growth-inhibitory activities of RAR, and 
allow cells to survive in the face of powerful apoptotic agents.  Hence, RA-dependent 
maintenance of skin integrity, proliferation of basal keratinocytes, and survival of 
these cells during wound repair likely stem from a high expression level of FABP5, 
enabling RA to activate PPARβ/δ.  Activation of PPARβ/δ by RA also appears to 
underlie the facilitation of mammary tumor progression in MMTVneu mice by this 
hormone.  In support of this conclusion are the observations that RA functions as 
anti-apoptotic agent in cells derived from MMTVneu tumors, that a high 
FABP5/CRABP-II ratio is required for this activity, that tumor progression in 
MMTVneu mice is accompanied by marked increase in the FABP5/CRABP-II ratio, 
and that decreasing this ratio by ectopic over-expression of CRABP-II triggers 
apoptosis and inhibits tumor development in vivo (Manor et al., 2003).  It is worth 
noting in regard to this that it has been reported FABP5 is expressed in melanocytic 
tumors, but not in normal human melanocytes (Brouard et al., 2002), indicating that 
elevation in the expression of this protein, and thus activation of 
PPARβ/δ accompanies tumorigenesis in various cancers.  While not directly 
addressed here, the observations that RA is critical for neuronal survival (Henion and 
Weston, 1994; Jacobs et al., 2006; Plum et al., 2001; Rodriguez-Tebar and Rohrer, 
1991; Wuarin et al., 1990) raise the possibility that the brain may comprise another 
organ in which RA signals through PPARβ/δ.  It is interesting to note regarding this 
possibility that the expression level FABP5 is high during neurogenesis in the 
developing rat brain (Liu et al., 2000), that this protein is required for neuronal 
outgrowth in PC12 neuronal cells (Allen et al., 2000), and that its expression is 
induced following nerve injury (De Leon et al., 1996), suggesting an involvement in 
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survival/repair processes. 
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3.1 Summary 
 
Retinoic acid (RA) displays potent anticarcinogenic activities which are mediated by 
the nuclear receptor RAR.  However, in some cancers, RA facilitates tumor growth.  
It was recently suggested that this paradoxical activity may be mediated by another 
receptor, PPARβ/δ, and that partitioning of RA between its two receptors is regulated 
by CRABP-II and FABP5, which target RA to RAR and PPARβ/δ, respectively.  
Here, we generated MMTV-neu mammary carcinoma mouse models that express 
varying mammary CRABP-II/FABP5 ratios.  We show that, in neoplasms of MMTV-
neu mice, RA does not activate RAR, but activates PPARβ/δ to enhance proliferation.  
Increasing the CRABP-II/FABP5 ratio diverts RA to RAR, thereby markedly 
suppressing tumor growth.  The data demonstrate the existence of a novel mechanism 
that underlies RA-resistance in tumors.   
 
3.2 Significance 
Despite promising clinical results, use of RA in oncology is limited  by RA-resistance 
acquired during carcinogenesis.  RA inhibits tumor growth by activating the nuclear 
receptor RAR, but the basis for development of RA-resistance remains incompletely 
understood.  We show that, in the RA-resistant mouse model of breast cancer MMTV-
neu, RA does not activate RAR but, instead, activates the ‘non-classical’ RA-receptor 
PPARβ/δ, thereby enhancing proliferation.  This behavior was traced to aberrant 
expression of CRABP-II and FABP5, which target RA to RAR and PPARβ/δ, 
respectively.  Increasing the CRABP-II/FABP5 ratio in mammary tissue diverted RA 
from PPARβ/δ to RAR and suppressed tumor growth.  Hence, CRABP-II is a tumor 
suppressor, and inhibition of FABP5 may comprise a novel therapeutic strategy for 
overcoming RA-resistance in tumors.
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3.3 Introduction 
The vitamin A metabolite all-trans-retinoic acid (RA) is a potent inhibitor of 
carcinogenesis and is currently used as a therapeutic agent in several types of human 
cancer (Altucci and Gronemeyer, 2001; Soprano et al., 2004). The anti-carcinogenic 
activities of this hormone are mediated by retinoic acid receptors (RARα, β, and γ), 
members of the nuclear receptor family of ligand-activated transcription factors.  Like 
other subclass 1 nuclear receptors, RARs interact with the retinoid X receptor (RXR) 
to form heterodimers that bind to DNA through RAR response elements in regulatory 
regions of specific target genes (Chambon, 1996; Kitareewan et al., 2002).  In the 
absence of RA, DNA-bound RAR associates with a corepressor complex which 
includes components that catalyze histone deacetylation, leading to a compact 
chromatin structure and transcriptional repression (Xu et al., 1999).  The first step in 
activation of the receptor entails delivery of RA from the cytosol to RAR in the 
nucleus.  This step is mediated by cellular retinoic acid binding protein II (CRABP-
II), a cytosolic protein that, upon binding RA, mobilizes to the nucleus, where it 
directly interacts with RAR to form a complex through which RA is ‘channeled’ to 
the receptor (Budhu et al., 2001; Budhu and Noy, 2002; Dong et al., 1999; Sessler 
and Noy, 2005).  Upon binding of RA, the C-terminal of RAR undergoes a large 
conformational change, leading to dissociation of corepressors and recruitment of a 
coactivator complex (Moras and Gronemeyer, 1998).  In turn, coactivators catalyze 
histone acetylation to loosen chromatin structure and enable transcription to proceed (Xu 
et al., 1999).  A different class of coactivators, termed Mediators, associate with 
liganded RAR and ‘bridge’ between the receptor and the general transcription 
machinery (Rachez and Freedman, 2001).   
Once activated, RAR upregulates the expression of multiple target genes 
including genes involved in differentiation (Park et al., 1999; Rochette-Egly and 
Chambon, 2001), cell cycle control (Donato et al., 2007), and apoptosis (Donato and 
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Noy, 2005; Gumireddy et al., 2003; Oltersdorf et al., 2005; Srivastava et al., 1999).  
Activated RAR thus often inhibits cell growth and it displays distinct 
anticarcinogenic activities (Altucci and Gronemeyer, 2001; Soprano et al., 2004).  
However, despite increased understanding of the mechanisms by which RA inhibits 
cancer cell growth and promising pre-clinical and clinical results, use of retinoids in 
cancer therapy and prevention remains limited.  Such therapy is hampered both by 
pronounced toxicity of RA when administered at pharmacological doses, and by the 
development of RA-resistance during carcinogenesis (Garattini et al., 2007; Mongan 
and Gudas, 2007).  It has been demonstrated that RA-resistance may stem from 
suppression of various steps of the overall process of transcriptional activation by the 
hormone.  Hence, in different carcinomas, such resistance has been reported to 
involve defects in RA synthesis (Arapshian et al., 2000), down-regulation of CRABP-
II (Budhu and Noy, 2002; Jing et al., 1997), loss of expression of RAR, in particular 
through epigenetic silencing of RARβ2 (Olasz et al., 2007; Xu, 2007), and impaired 
ligand-induced corepressor/coactivator exchange (Slack, 1999).  Accordingly, it has 
been demonstrated that RA-responsiveness may be restored to carcinomas by 
targeting specific repressed steps, e.g. by ectopic expression of CRABP-II (Budhu 
and Noy, 2002; Manor et al., 2003) or RARβ2 (Campbell et al., 1998; Hoffman et al., 
1996), and by chemical inhibition of histone deacetylases (He et al., 2001; Warrell et 
al., 1998).   
Notably, various reports indicated that some carcinomas not only display 
“RA-resistance”, i.e. a failure to become growth-inhibited upon treatment with the 
agent, but, instead, administration of RA to these cells confers enhanced proliferation.  
For example, it was reported that RA treatment facilitates skin tumor formation 
(Verma et al., 1982), enhances tumor growth in the MMTV-neu mouse model of 
breast cancer (Schug et al., 2007), augments proliferation induced by epidermal 
growth factor in cultured explants of mouse mammary gland (Komura et al., 1986), 
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and, under some circumstances, promotes at late stages of malignant progression 
(Sapi et al., 1999).  In addition, the β-Carotene and Retinol Efficacy Trial (CARET), 
a multicenter lung cancer chemoprevention trial with smoker and asbestos-exposed 
populations was terminated in 1996, 21 months ahead of schedule, due to the findings 
that the treatment resulted in 28% increase in lung cancer incidence and in 46% 
higher mortality rate from lung cancer (Omenn et al., 1996).  While these effects may 
have potentially stemmed from RA-independent activities or retinol or β-carotene, the 
observations support the notion that, under some conditions, retinoids possess 
procarcinogenic activities.  Such activities are unlikely to be mediated by RAR. 
Proproliferative, RAR-independent activities of RA were also suggested by the 
observations that, although this hormone plays critical roles in maintenance of skin 
integrity, all RAR subtypes are dispensable for keratinocyte renewal (Chapellier et 
al., 2002).   
A clue as to a possible basis for the RAR-independent activities of RA was 
recently provided by the observations that this hormone also serves as a ligand for 
another nuclear receptor, namely, PPARβ/δ.  It was thus demonstrated that RA binds 
to PPARβ/δ with a high affinity, and that it induces the ability of the receptor to 
transactivate reporter gene constructs as well as endogenous target genes (Schug et 
al., 2007; Shaw et al., 2003).  In view of the reports that target genes for PPARβ/δ 
include genes involved in proliferative responses, such as VEGF (Wang et al., 2006), 
and genes that activate survival pathways, e.g. PDK1 (Di-Poi et al., 2002; Icre et al., 
2006; Tan et al., 2004), it was suggested that activation of this receptor by RA may 
underlie pro-proliferative activities of the hormone.  It was shown in regard to this 
that RA-triggered activation of PPARβ/δ in keratinocytes protects these cells against 
apoptosis triggered by the potent apoptotic agent TNFα (Schug et al., 2007)   
The observations that RA can activate both RAR and PPARβ/δ raise the 
question of the mechanism that regulate the partitioning of the hormone between the 
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two receptors.  The key to this transcriptional targeting was found to lie with two 
intracellular lipid-binding proteins: CRABP-II which delivers RA to RAR (Budhu et 
al., 2001; Budhu and Noy, 2002; Dong et al., 1999; Sessler and Noy, 2005), and 
FABP5 (K-FABP, eFABP, mal1), a CRABP-II-homolog which targets the hormone 
to PPARβ/δ (Schug et al., 2007; Tan et al., 2002).  Similarly to CRABP-II, FABP5 
mobilizes to the nucleus upon binding of RA but, while CRABP-II delivers RA to 
RAR, FABP5 channels the ligand to PPARβ/δ (Schug et al., 2007).  Indeed, it was 
demonstrated that RA signals through RAR and inhibits the growth of cells that 
express a high level of CRABP-II, but functions predominately through PPARβ/δ and 
displays anti-apoptotic activities in cells that contain a high FABP5/CRABP-II ratio 
(Schug et al., 2007).  
These observations suggest that the RA-resistance of some tumors may result 
from targeting of RA to PPARβ/δ rather than to RAR.  To examine this hypothesis, 
we used the FVB/N-Tg(MMTVneu)202Mul/J (MMTV-neu) transgenic mouse model 
of breast cancer.  In this model, Neu/Erb-B2/Her2, which encodes for a member of 
the epidermal growth factor receptor protein tyrosine kinase family, is specifically 
over-expressed in the mammary epithelium under the control of MMTV-LTR 
promoter/enhancer, resulting in spontaneous development of mammary tumors in 
100% of female mice (Guy et al., 1992).  Amplification of this gene has been 
observed in a significant proportion of primary human breast cancers (King et al., 
1985; Yokota et al., 1986), and a strong correlation has been established between the 
extent of overexpression and poor outcome in human patients (Slamon et al., 1989).  
Notably, over-expression of Neu induces profound RA-resistance in cultured cells 
(Tari et al., 2002) as well as in vivo (Schug et al., 2007).  The basis for this resistance 
is currently unknown.  However, the observations that carcinogenesis in MMTV-neu 
mice is accompanied by an increase in the FABP5/CRABP-II ratio in tumors (Schug 
et al., 2007), and that administration of an adenovirus encoding CRABP-II to these 
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tumors suppresses their growth (Manor et al., 2003) raise the possibility that the RA-
resistance of these tumors originates from deregulation of the expression ratio of the 
two RA-binding proteins, which, in turn, may lead to RA signalling through 
PPARβ/δ rather than through RAR.  To examine this hypothesis, we generated 
MMTV-neu mice models with varying mammary FABP5/CRABP-II ratios and 
investigated the transcriptional activities of RA and the outcomes of these activities 
for tumor development in these mice.   
 
3.4 Results 
Generation of transgenic mice with varying mammary FABP5/CRABP-II ratios.  
To explore the possibility that changes in the expression ratio of CRABP-II and 
FABP5 determine cellular responses to RA signaling in vivo, we generated two new 
MMTV-neu mammary carcinoma mouse models.  One of these consisted of MMTV-
neu mice in which expression of CRABP-II is disrupted, leading to a very high 
FABP5/CRABP-II ratio.  This model was established by crossing MMTV-neu mice 
with CRABP-II-null mice (Lampron et al., 1995), resulting in MMTV-neu+/-/CRABP-
II-/-  mice (termed MCRABP-II-/- in this manuscript). (see Experimental Procedures 
for details of crosses).   
A second model entailed MMTV-neu mice that specifically over-express 
CRABP-II in mammary tissue and thus display a low FABP5/CRABP-II ratio.  Such 
mice were generated using a transgenic construct consisting of the mammary 
epithelium-specific promoter/enhancer MMTV-LTR, derived from the mouse 
mammary tumor virus, a synthetic human CRABP-II cDNA construct, and a human 
beta globin polyadenylation signal (Fig 3.1a).  Transgenic founders were identified by 
PCR, and gene integration confirmed by Real Time quantitative PCR (Q-PCR).  
Mammary expression of the transgene was verified by immunoblotting, and by Q-
PCR analysis of mammary glands and other tissues (Fig 3.1b-3.1d).  These mice were 
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crossed with MMTV-neu mice to generate MMTV-neu+/-/MMTV- CRABP-II animals 
(termed here MTgCRABP-II). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Generation of transgenic mice.  (a) Mice over-expressing CRABP-II in 
the mammary gland (MMTV-CRABP-II) were generated using a targeting construct 
consisting of the mammary tissue-specific promoter/enhancer (MMTV-LTR) derived 
from the mouse mammary tumor virus, a synthetic human CRABP-II cDNA 
construct, and a mammalian beta globin polyadenylation signal. (b) Primer-specific 
detection of hCRABP-II transgenic construct. (c) Expression levels of CRABP-II in 
mammary tissue of MMTV-neu (Mneu) MMTV-neu/MMTV-CRABP-II (MTg-II), and 
MMTV-neu-CRABP-II-/- (MII-/-) mice were assessed by immunoblotting. (d) 
Expression levels of mRNA for hCRABP-II and mCRABP-II in transgenic and 
control mouse tissues, measured by Q-PCR and normalized to 18s mRNA. Data are 
mean±SEM, n=3. 
  74 
 
Expression levels of RA receptors and binding proteins in tumors that develop in 
the mouse models.  To begin to characterize RA signalling in tumors that develop in 
MMTV-neu mice and in their counterparts that either over-express CRABP-II in 
mammary tissue, or lack the protein, the levels of expression of the two RA receptors, 
RAR and PPARβ/δ, and the two RA binding proteins, CRABP-II and FABP5, were 
examined (Fig. 3.2).  As previously noted (Schug et al., 2007), carcinogenesis in 
MMTV-neu mice is accompanied by downregulation of CRABP-II and upregulation 
of FABP5 (Fig. 3.2a and 3.2d).  As expected, the expression of CRABP-II was not 
detectable in tumors of the MCRABP-II-/- mice, and was markedly elevated in mice 
that transgenically over-express the protein in mammary tissue (Fig. 3.2a).  
Examination of the level of expression of RAR by immunoblots utilizing RAR 
antibodies that recognize all three RAR subtypes revealed that this receptor is down-
regulated upon tumor development in MMTV-neu mice (Fig. 3.2b). Q-PCR analyses 
showed that expression of all three RAR isotypes are lower in tumors as compared to 
normal mammary tissue, and that RARβ displayed the largest response, showing a 
40-50% lower level in tumors relative to normal mammary tissue (Fig. 3.2c).  
Importantly, similar expression levels of RAR mRNAs were observed in all three 
mice models, indicating that they can be directly compared.  RAR expression could 
not be restored by RA treatment of the mice (Fig. 3.2c).  Expression levels of both 
FABP5 and PPARβ/δ were similar in all three mouse models (Fig. 3.2d-3.2f).  Hence, 
tumors that develop in the three MMTV-neu mouse models express similar levels of 
RARs and PPARβ/δ,  but they display large differences in the ratio of expression of 
CRABP-II and FABP5.   
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Figure 3.2. Levels of RA receptors and binding proteins in tumors that develop 
in the mouse models. (a.)  Immunoblots of CRABP-II measured in tumors of 
MMTV-neu (Mneu), MMTV-neu/MMTV-CRABP-II (MTg-II), and MMTV-
neu/CRABP-II-/- (MII-/-) mice.  (b.) Expression levels of total RAR in normal 
mammary tissue and in mammary tumor in MMTV-neu mice, measured by  
immunoblotting. (c.) Expression levels of mRNA for RAR isotypes (α, β, γ) in 
tumors that arose in the denoted mouse models, and in MMTV-neu mice subjected to 
systemic RA as of age 140 d (+RA), measured by Q-PCR. (d)  Immunoblots of 
FABP5 in normal mammary tissue, and in tumors that arose in the denoted mouse 
models. (e)  Expression of FABP5 mRNA in tumors that arose in the denoted mouse 
models. (f) Expression levels of PPARβ/δ mRNA in tumors that arose in the mouse 
models and in MMTV-neu mice treated with RA.  Levels of mRNA were normalized 
to 18s mRNA. 
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In MMTV-neu mice tumors, RA signals through PPARβ /δ , and is diverted to 
RAR upon increasing the CRABP-II/FABP5 ratio.   To examine the possibility 
that the RA-resistance of tumors that arise in MMTV-neu mice may stem from RA 
signalling through PPARβ/δ, mice were systemically treated with RA (see 
Experimental Procedures), tumors were allowed to develop, and the intra-tumor 
expression levels of known target genes for RAR and PPARβ/δ were measured.  
Tumors with 1 cm3 volumes were removed, RNA extracted, and gene expression was 
assessed by Q-PCR.  The data (Fig. 3.3a) showed a marked RA-induced upregulation 
of mRNA for the direct PPARβ/δ target genes fasting-induced adipose factor (FIAF, 
(Kersten et al., 2000)) and adipose differentiation-related protein (ADRP, (Schmuth et 
al., 2004)), as well as PDK1, a kinase that activates the Akt-1 survival pathway and 
thus mediates potent anti-apoptotic activities (Di-Poi et al., 2002; Tan et al., 2001).  
In contrast, RA treatment had little effect on the expression of the direct RAR target 
genes caspase 9 and BTG2, or the indirect target cyclin D1 (Donato and Noy, 2005; 
Donato et al., 2007) (Figure 3.3b).  Hence, RA in these tumors does not activate RAR 
but, instead, induces transcriptional activation by PPARβ/δ. 
To examine whether alteration in the expression ratio of CRABP-II and 
FABP5 modulates the ability of RA to activate the two receptors, expression levels of 
target genes for RAR and for PPARβ/δ were measured in tumors that arise in MMTV-
neu mice that over-express CRABP-II and thus have a low FABP5/CRABP-II ratio 
(MTgCRABP-II), and in mice that lack CRABP-II (MCRABP-II-/-).  The data (Fig. 
3.3c) demonstrated that the expression of all three PPARβ/δ target genes was 
significantly reduced in the presence of a low FABP5/CRABP-II ratio, and was 
upregulated in the absence of CRABP-II.  In contrast, the direct RAR target genes 
caspase 9 and BTG2 were markedly upregulated upon over-expression of CRABP-II, 
and their expression decreased in mice lacking this binding protein (Fig. 3.3d).  
Another RAR-controlled gene involved in cell cycle regulation is cyclin D1, a down-
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stream effector whose expression is down-regulated by BTG2 (Donato et al., 2007; 
Guardavaccaro et al., 2000; Kawakubo et al., 2004).  Over-expression of CRABP-II 
decreased cyclin D1 expression, while ablation of this binding protein results in an 
increased level.  Hence, a low FABP5/CRABP-II ratio depresses the expression of 
PPARβ/δ target genes including anti-apoptotic genes, and leads to gene expression 
commensurate with cell cycle arrest and enhanced apoptotic responses.  Interestingly, 
Apaf1, the major protein in the apoptosome, is not subject to regulation by RAR, but 
it has been reported that its expression is upregulated in cultured mammary carcinoma 
cells ectopically overexpressing CRABP-II.  It has been further shown that this effect 
is exerted in the absence of RA (Donato and Noy, 2005).  The observations that 
Apaf1 expression is also markedly upregulated upon over-expression of CRABP-II in 
vivo (Fig. 3.3d) suggests that, in addition to its cooperation with RAR, this binding 
protein may contribute to apoptotic responses through another, as yet unknown, 
mechanism. 
Changing the CRABP-II/FABP5 ratio alters RA activities in cell lines generated 
from tumors of MMTV-neu mice.   The role of the CRABP-II/FABP5 ratio in 
regulating cellular responses to RA was further investigated by utilizing cell lines 
generated from tumors that developed in MMTV-neu mice with varying 
FABP5/CRABP-II ratios (see Experimental Procedures for details).   
In accordance with the expression profile in vivo, NaF cells, generated from 
MMTV-neu tumors (Elson and Leder, 1995), display a high FABP5/CRABP-II ratio 
((Schug et al., 2007) and Fig. 3.4a, 3.4b).  Cells generated from MMTV-neu mice with 
transgenic mammary over-expression of CRABP-II and from MCRABP-II-/- mice 
similarly retained the binding protein expression profiles observed in vivo (Fig. 3.4a, 
3.4b).  Also similarly to the in vivo behavior, CRABP-II-null cells displayed a 
decreased expression of the RAR target gene Cyp26a (White et al., 2000), and an 
increased expression of the PPARβ/δ target PDK1 as compared with cells over-  
  78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Increasing the CRABP-II/FABP5 ratio in MMTV-neu mice directs 
RA from PPARβ /δ to RAR. (a and b) Expression levels of mRNA for the denoted 
genes in tumors that arose in untreated female MMTV-neu mice and in mice 
systemically treated with RA as of age 140 days. (a.) Levels of mRNA for PPARβ/δ 
target genes. *p<0.01 vs.untreated mice; (b.) Levels of mRNA for RAR-controlled 
genes. (c and d) Expression levels of mRNA for target genes for PPARβ/δ (c) and 
RAR (d) in tumors thsat arose in the denoted mouse models.  *p<0.01 as compared to 
MMTV-neu controls.  Levels of mRNA were normalized to 18s mRNA. Data 
(mean±SEM) were analyzed with 2-tailed Student’s t tests with pool variances (n=3). 
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expressing this binding protein (Fig. 3.4c).  RA treatment upregulated the expression 
of the RAR target gene in cells with a high CRABP-II level, but induced the 
PPARβ/δ target in CRABP-II-/- cells (Fig. 3.4c). 
 
To examine the functional consequences of these differential transcriptional 
activities, the ability of RA to inhibit the growth of the cell lines was assessed by 
measuring incorporation of bromodeoxyuridine (BrdU), which reports on DNA 
synthesis and thus on cell proliferation.  Cells that over-express CRABP-II displayed 
a lower proliferation index and were markedly more sensitive to RA-induced growth 
inhibition as compared with cells lacking this binding protein (Fig. 3.4d).  The role of 
the binding proteins was further investigated by examining the ability of RA to 
induce apoptosis.  Cells were treated with either RA or the apoptosis inducer TRAIL, 
and apoptosis was assessed by monitoring the cleavage/activation of caspase 3 (Fig. 
3.4e and 3.4f).  In cells expressing a high CRABP-II/FABP5 ratio, both TRAIL and 
RA induced apoptosis.  Strikingly, cells lacking CRABP-II displayed a markedly 
lower level of cleaved caspase 3, and RA, unlike TRAIL, decreased this level even 
further.  Hence, RA induces apoptosis in the presence of a high CRABP-II/FABP5 
ratio, but becomes an anti-apoptotic agent in cells in which this ratio is reversed.  
 
Decreasing the FABP5/CRABP-II ratio induces apoptosis and suppresses 
mammary tumor growth in MMTV-neu mice.  These observations suggest that 
decreasing the FABP5/CRABP-II ratio diverts RA from PPARβ/δ to RAR, and that 
this ‘switch’ results in growth inhibitory activities.  To examine this notion, the rate 
of growth of mammary tumors in MMTV-neu mice with varying levels of expression 
of CRABP-II was studied.  Measurements of tumor size were initiated when tumors 
reached a volume of 0.065cm3. The data (Fig. 3.5a, 3.5b, and Table 3.1) showed that 
tumor growth in CRABP-II-null was significantly facilitated, while mammary over- 
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Figure 3.4. Effects of varying the CRABP-II/FABP5 ratio on RA activities in cell 
lines derived from MMTV-neu mice tumors.  (a,b) Immunoblots of CRABP-II (a) 
and FABP5 (b) in cell lines derived from tumors that arise in MMTV-neu (NaF), 
MMTV-neu/MMTV-CRABP-II (MTg-II), and MMTV-neu/CRABP-II-/- (MII-/-)mice.  
(c)  Expression levels of mRNA for the RAR target gene Cyp26a, and the PPARβ/δ 
target PDK-1 in the denoted cell lines.  Cells were treated with 0.1 µM RA for 4 hr., 
lysed, and total RNA extracted and analyzed by Q-PCR.  *p=0.05 and **p<0.001 as 
compared to untreated MTg-II cells.  #p<0.01 as compared to untreated MTg-II cells; 
##p<0.01 as compared to untreated MII-/- cells.  (d) BrdU incorporation. Denoted cell 
lines were treated with 1 µM RA for 24 hr., cell  proliferation was monitored using a 
BrdU cell proliferation assay (Calbiochem). *p=0.03 and **p=0.02 as compared to 
untreated MTg-II cells.  (e) Denoted cell lines were with RA (1 µM, 12 hr.) or TRAIL 
(10 ng/ml, 12 hr). Cells were lysed and the level of cleaved caspase 3 assessed by 
immunoblots. (f) Quantitation of the experiment described in (e).  
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expression of CRABP-II markedly delayed tumor growth.  Mice with an elevated 
mammary CRABP-II/FABP5 ratio also displayed a lower number of tumors per mice, 
and, strikingly, while tumors developed in 100% of mice in other groups, 4 out of 13 
MTg-CRABP-II mice remained tumor-free throughout the duration of the experiment 
(Table 3.1). 
 
Table 3. 1  Tumor growth in MMTV-neu mice with varying CRABP-II 
expression levels  
 
genotype mice with 
tumors 
tumors/mice tumor volume 
day 20  
(cm3, 
mean±SE)* 
median 
survival 
(days)** 
MMTV-neu 22/22 2.3 0.68±0.20 399 
MCRABP-II -/-  9/9 2.3 0.80±0.23 326 
MTg-CRABP-II 9/13 1.3 0.32±0.09 513 
 
Number and volumes of tumors arising in the different mouse models.  *Tumor 
volumes are mean ±SE, p= 0.00256 comparing MTg-CRABP-II to MCRABP-II-/- , 
and p=0.000321 comparing MTg-CRABP-II to MMTV-neu mice.  **Survival rate of 
mice was defined as the age in which tumor reached 0.524 cm3.  p=0.005 and =0.013 
comparing MTg-CRABP-II and MCRABP-/- to MMTV-neu controls, respectively.   
Survival fractions were calculated using the Kaplan-Meier method.  Survival curves 
were compared by log rank Mantel-Haenszel tests. Means were compared by 
estimation of the two-tailed P with unpaired t tests.  
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All mammary neoplasms in the three cohorts of mice were  adenocarcinomas, 
however, some differences were observed.  In agreement with previous studies of the 
MMTV-neu model (Cardiff et al., 2000; Cardiff et al., 1991), adenocarcinomas in the 
control mice were composed of solid sheets of neoplastic epithelial cells with little or 
no glandular differentiation (Fig. 3.5c).  Neoplastic population consisted of uniform 
densely packed relatively small cells with eosinophilic cytoplasm and rounded to 
elongated nuclei with diffuse chromatin pattern.  Mitotic figures were observed often  
alongside with few apoptotic cells or bodies.  In MTg-CRABP-II mice, the majority 
of tumors (16 out of 18) contained areas of adenocarcinomas with larger cells 
organized in nests or bundles separated by thin bands of connective tissue and blood 
vessels (Fig. 3.5d).  The nuclei of the tumor cells were larger, with more open 
chromatin pattern, giving them vesicular appearance with prominent nucleoli and 
clumped heterochromatin. Such areas varied from 10-30% to over 90% of neoplasms. 
Single mitotic figures as well as apoptotic cells were seen.  The adenocarcinomas in 
the MCRABP-II-/- mice were with solid/nodular growth, more similar to MMTV-neu 
model. Their cells were densely packed, with pale eosinophilic cytoplasm and scanty 
connective tissue. In 8 out of 12 tumors there were areas of cells with nuclei of 
intermediate size and open chromatin pattern (Fig. 3.5e). Numerous mitoses and few 
apoptotic cells were seen. 
 
To obtain further insight into the mechanism through which alteration in the  
FABP5/CRABP-II ratio modulate tumor growth, proliferation and apoptosis in 
tumors that arise in the different mouse models were evaluated. Immunostaining for 
the proliferation marker Ki67 (Fig. 3.6a-3.6c and 3.6g) showed a significant decrease 
in proliferation neoplasms of mice over-expressing CRABP-II, and a slight increase 
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Figure 3.5. Mammary tumor growth in MMTV-neu mice expressing varying 
FABP5/CRABP-II ratios.  Tumor growth was monitored in female MMTV-neu+/- 
(MMTV-neu), MMTV-neu/MMTV-CRABP-II (MTg-CRABP-II), and MMTV-
neu/CRABP-II-/- (MCRABP-II-/-) mice.  (a) Tumor sizes in the denoted groups were 
measured with calipers with a start point (day 0) of tumor volume = 0.065 cm3. (b) 
Kaplan-Meier survival curves.  Mouse survival was defined as the age in which tumor 
volume reached 0.524 cm3.  (c-e) Hematoxylin and eosin staining of mammary 
tumors that arose in the mouse models. (c) Mammary carcinoma in an MMTV-neu 
mouse.  Solid growth of dense relatively small tumor cells with round dark nuclei.  
Mitotic figures (arrows) and few apoptotic cells (arrowhead) are seen.  (d) Mammary 
carcinoma in an MTg-CRABP-II mouse. The cells are lager, with vesicular nuclei and 
prominent nucleoli and heterochromatin. They are arranged in small nests or bundles 
separated by thin connective tissue bands. Apoptotic cells (arrowhead) are seen.  (e) 
Mammary carcinoma in an MCRABP-II-/- mouse. Solid growth of cells with dense 
chromatin and frequent mitotic figures (arrows). Bar, 75 µm. 
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Figure 3.6. Varying the FABP5/CRABP-II ratio affects proliferation and 
apoptosis of neoplastic cells in tumors of MMTV-neu mice. (a-c.) Proliferation of 
tumor cells detected by immunostaining with antibodies toward Ki67 (brown).  (a) 
An MMTV-neu tumor; (b) An MTg-CRABP-II tumor; (c). An MCRABP-II-/- tumor.  
(d-f) Detection of apoptotic cells by immunostaining for cleaved-caspase 3 (brown). 
(d) An MMTV-neu tumor; (e) An MTg-CRABP-II tumor; (f) An MCRABP-II-/- 
tumor.  Calibration bar, 75µm. (g)  Quantitation of proliferation levels measured as 
the percentage of Ki67-stained cells. *p=0.022, **p=0.057 vs. MMTV-neu controls. (h) 
Quantitation of apoptotic index measured as the percentage of cleaved caspase-3-
stained cells. *p=0.002, **p=0.067 vs. MMTV-neu controls. Quantitations were 
performed as described under Experimental procedures. Data (mean±SEM) were 
analyzed with 2-tailed Student’s t tests with pool variances (n=3). 
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in proliferation in the CRABP-/- tumor. On the other hand, the fraction of apoptotic 
cells, evaluated by immunostaining for cleaved caspase 3, was markedly higher in 
mammary tumors arising from mice overexpressing CRABP-II compared to either the 
CRABP-II-null mice or the MMTV-neu controls (Fig. 3.6d-3.6f, and 3.6h).   
 
3.5 Discussion 
RA displays pronounced anticarcinogenic activities and is currently used in therapy 
of some cancers and is being tested for treatment of others.  Most notably, the ability 
of RA to target the oncogenic promyelocytic leukemia-RAR fusion protein renders 
RA a powerful therapeutic agent in treatment of PML (Lengfelder et al., 2005).  
However, RA therapy of cancer is hampered both by pronounced toxicity and by the 
development of RA-resistance in tumors and, consequently, general use of this agent 
in oncology remains limited.  RA-resistance in tumors has been shown to originate 
from various defects in RA signalling but remains incompletely understood.  
Moreover, in some cases, RA treatment not only fails to inhibit carcinoma cell growth 
but, instead, results in facilitated tumor development, as exemplified by the marked 
RA-induced acceleration of mammary tumor development in the mouse model of 
breast cancer MMTV-neu (Schug et al., 2007). 
It is well established that many cellular responses to RA are mediated by the 
nuclear receptor RAR, which, in various carcinomas, upregulates the expression of 
genes that evoke differentiation, cell cycle arrest, and apoptosis, thereby inhibiting 
cell growth.  The ability of RA to function in a contrary fashion, i.e. to enhance tumor 
development, is thus unlikely to be mediated by RAR, and the basis for this behavior 
has long remained an enigma.  The recent reports that, in addition to activating RAR, 
RA also serves as a ligand for PPARβ/δ (Schug et al., 2007; Shaw et al., 2003), a 
nuclear receptor that targets genes involved in mitogenic responses and in survival 
pathways (Di-Poi et al., 2002; Icre et al., 2006; Tan et al., 2004; Wang et al., 2006), 
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suggests a possible mechanism through which RA may facilitate tumor growth.  
Importantly, it was also suggested that the partitioning of RA between the two 
receptors and thus, regulation of anti-proliferative vs. proliferative responses to RA, is 
controlled not by the receptors themselves but by two intracellular lipid-binding 
proteins that deliver the ligand to them: CRABP-II which channels RA to RAR, and 
FABP5 which specifically shuttles RA to PPARβ/δ (Schug et al., 2007).  We thus set 
out to explore the hypothesis that the facilitated development of mammary tumors in 
MMTV-neu mice in response to RA may originate from an aberrantly high 
FABP5/CRABP-II expression ratio in these tumors which, in turn, may channel RA 
to PPARβ/δ rather than to RAR.  
The data show that this is indeed the case.  Examination of gene expression 
profiles in tumors that arise in female MMTV-neu mice revealed that, in these tumors, 
RA upregulates the expression of PPARβ/δ target genes, including the survival factor 
PDK1, but is not able to induce the expression of cell cycle control and apoptotic 
RAR targets.  Increasing the already high FABP5/CRABP-II ratio results in further 
elevation of PPARβ/δ targets and further decrease in genes regulated by RAR.  On 
the other hand, a decreased FABP5/CRABP-II ratio in tumors diverted RA from 
PPARβ/δ to RAR, upregulated the apoptosis factor caspase 9 and the cell cycle 
control protein BTG2, and downregulated cyclin D1.  Correspondingly, neoplastic 
cells in mammary carcinomas of MCRABP-II-/- and MMTV-neu mice displayed 
numerous mitotic figures and a high proliferation rate, while those of tumors that 
overexpress CRABP-II were characterized by reduced proliferation and a high 
apoptotic rate.  Interestingly, slower growth of neoplasms that overexpress CRABP-II 
was accompanied by changes in morphology and growth pattern of neoplastic cells, 
which may indicate a more differentiated state. Lowering the FABP5/CRABP-II ratio 
thus attenuated proliferation, enhanced apoptosis, changed cell morphology and 
markedly inhibited tumor growth.   
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Varying the expression level of CRABP-II in mammary tumors also markedly 
affected the expression Apaf1, the major protein in the apoptosome.  The effect 
recapitulates in vivo the previously reported observation that CRABP-II expression 
upregulates Apaf1 in MCF-7 mammary carcinoma cells.  In the cultured cells, this 
effect was found to take place in the absence of RA and it was thus suggested that the 
activity stems from an RAR-independent activity of the binding protein (Donato and 
Noy, 2005).  Hence, pro-apoptotic activities of CRABP-II may originate both from its 
cooperation with RAR and from an additional function, the nature of which is 
currently unknown. 
Remarkably, the FABP5/PPARβ/δ pathway was found to facilitate, and 
CRABP-II/RAR signalling suppressed tumor growth in the absence of ectopic 
administration of RA, i.e. at the level of RA endogenously present in the mouse.  
Hence, strategies that target the two binding proteins may dramatically reduce the 
doses of RA needed for efficacious treatment, and bypass both the RA-resistance of 
tumors and the toxicity barrier encountered in current therapies.  These observations 
point at the conclusion that CRABP-II functions as a potent tumor suppressor, and 
suggest further that inhibition of FABP5 may comprise a novel strategy for treatment 
of some cancers.  While no antagonists for this protein currently exist, a recent report 
demonstrated the development of a small molecule inhibitor for the homologous 
protein FABP4 (A-FABP, aP2).  In the case of FABP4, it was shown that such an 
inhibitor is an effective therapeutic agent against atherosclerosis and type 2 diabetes 
in mouse models (Furuhashi et al., 2007).  Together with the data reported here, these 
observations suggest that compounds that target intracellular lipid-binding proteins 
may comprise a new class of therapeutic agents.  Development of such compounds 
could be greatly assisted by the recent delineation of the structural features that 
underlie the ability of specific ligands to activate intracellular lipid-binding proteins, 
including CRABP-II, FABP5 and FABP4 (Ayers et al., 2007; Gillilan et al., 2007; 
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Sessler and Noy, 2005). 
 
3.6 Experimental Procedures 
Reagents.  Antibodies against CRABP-II were provided by Cecile Rochette-Egly 
(Gaub et al., 1998).  Antibodies against FABP5, RAR, and cleaved caspase 3 were 
purchased from R&D, Santa Cruz Biotechnology, and Cell Signaling Technologies, 
respectively.  Anti-mouse and anti-rabbit immunoglobulin horseradish peroxidase-
conjugated antibody were purchased from Amersham/GE Healthcare Life Sciences 
and BioRad Laboratories, respectively. RA and TRAIL were from Calbiochem and 
Sigma Chemical Co., respectively. RA was dissolved in ethanol.  
Construction of the MMTV-CRABP-II transgene and generation of transgenic 
mice.  To construct the MMTV-CRABP-II-beta globin pA transgene, the 414 bp 
hCRABP-II EcoR1-BamH1 fragment from pSG5 was ligated to the 427 bp BgIII-
Pac1 human beta globin polyadenylation signal fragment from pBroad, and cloned 
into pMAMneo containing the mammary epithelium specific promoter/enhancer 
MMTV-LTR. The 2.39-kb MMTV-LTR-CRABPII beta globin pA transgene was 
released by restriction with Nhe and Spe, purified, and injected into the pronuclei of 
fertilized FVB/N oocytes by the Transgenic Facility of Cornell University College of 
Veterinary Medicine. Transgenic founders were identified by PCR, and copy number 
was confirmed by Real Time quantitative PCR (Q-PCR). 
Mouse breeding .  Colonies of MMTV-neu and MMTV-CRABP-II mice were 
maintained on FVB/N background.  CRABP-II-/- mice were on a C57BL/6 
background.. The MMTV-neu+/-/CRABP-II-/- model was established by crossing 
FVB/N-Tg(MMTVneu)202Mul/J (MMTV-neu; Jackson Laboratories, stock #002376) 
mice, which are homozygous for the neu transgene (neu+/+), with C57BL/6 CRABP-
II-/-) mice (provided by the laboratory of Pierre Chambon (Lampron et al., 1995)).  
The first generation of crossed mice (F1) were bred with CRABP-II-/- males to yield 
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the MMTV-neu+/-/CRABP-II-/- cohort (termed MCRABP-/- in this manuscript), and 
MMTV-neu+/-/CRABP-II+/- littermates, which were used as a control (termed 
MMTV-neu). Initial studies demonstrated that rate of mammary carcinogenesis on 
the F1 FVB/NXC57BL/6 background is similar to that on FVB/N background, and, 
thus, is appropriate for described experiments (not shown). MMTV-CRABP-II mice 
were crossed with MMTV-neu mice to generate MMTV-neu+/-/MMTV-CRABP-II 
animals (termed here MTgCRABP). All mice were maintained identically, following 
recommendations of the Institutional Laboratory Animal Use and Care Committee. 
Genotyping. DNA was isolated essentially as described (Nikitin et al., 1993). 
Transgenic mice were identified by PCR using primers for CRABP-II cDNA were 5'-
AGC AGT GGA GAT CAA ACA GGA GGG A-3' (CRABP-II hex2–5', sense), 5'-
CAG CAG TCG AGA TCA AAC AGG AGA A-3' (CRABP-II mex2–5', sense), and 
5'-AAG TTC CCA CTC TCC CAT TTC ACC A-3' (CRABP-II uex3–3', antisense). 
Primers CRABP-II hex2–5' and CRABP-II mex2–5' are specific for human and 
mouse exon 2, respectively. The primer CRABP-II uex3–3' recognizes both human 
and mouse sequence in exon 3 (Manor et al., 2003). Amplification of genomic and 
cDNA results in 345-bp and 159-bp PCR fragment, respectively. MMTV-neu/ 
CRABP-II-/- transgenic mice were identified by primers CRABP-II5' (5'-TAC TGA 
TGC GGG AGA AGG GTA TCT T-3'), CRABP-II3' (5'-GCC AGA  AAA GTT 
AGG CA TAGT GGC A-3'), TKP13’ (5'-GCC TGC TCT TTA CTG AAG GCT CTT 
T-3'). The MMTV-neu transgene was identified by primers Neu5’ (5'-GCC AGC 
CCG GTG ACA TTC ATC ATT G-3'),  and Neu 3’ (5'-CCG CAT CTG AGC CTG 
GTT GGG CAT T-3') (Nikitin et al., 1993). The PCR temperature profile was 94°C 
for 30 s, 60°C for 1 min., and 72°C for 2 min. with extension of the last cycle for 10 
min. at 72°C. 
Biochemical procedures.  Cell and tissue extractions and immunoblot analyses were 
performed as previously described (Schug et al., 2007).  For real time quantitative 
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PCR (Q-PCR) analyses, RNA was extracted using RNeasy (Qiagen, Valencia, CA), 
and cDNA was generated using Gene Amp RNA PCR (Applied Biosystems, Foster 
City, CA).  Q-PCR was carried out using TaqMan chemistry and Assays on Demand 
probes (Applied Biosystems) for CRABP-II  (Hs00275636_ml, Mm),  PDK-1 
(Mm00176884_m1),  FIAF (Mm00480431_m1), ADRP (Mm00475794_m1), 
Cyp26a (Mm00514486_m1), BTG2 (Mm00476162_m1), cyclin 
D1(Mm00432359_m1), RARα  (Mm00436264_m1), RARβ (Mm01319674_m1), 
RARγ (Mm00441083_m1), PPARβ/δ (Mm00803186_g1), FABP5 
(Mm00783731_s1).  18s rRNA (4319413E-0312010) was used as a control. Analyses 
were carried out using the relative standard curve method (Applied Biosystems 
Technical Bulletin no. 2). 
Carcinogenesis studies. All experiments were performed on multiparous females 
bred thrice. RA was administered by 90-day release 15 mg pellets (Innovative 
Research of America, Sarasota, Florida) implanted s.c.  Mammary tumor 
development was monitored by palpation three times per week, and tumor sizes were 
measured with calipers and recorded without investigator's knowledge of study 
groups.  
Pathological assessment. Complete necropsies and gross and microscopic 
examination of mice and tissues were performed.  Tissue samples from internal 
organs (heart, lung, liver, spleen, brain kidney, adrenal glands), mammary glands and 
tumors were collected, fixed in buffered paraformaldehyde overnight at 4oC and 
embedded in paraffin. Sections (4 µm thick) were mounted on glass slides and stained 
with hematoxylin and eosin. For biochemical analyses a part of material was snap-
frozen in liquid nitrogen. 
Immunohistochemical analyses. Immunostaining of paraffin sections of 
paraformaldehyde-fixed tissue was performed by a modified avidin-biotin-peroxidase 
(ABC) technique (Nikitin et al., 2002).  Antigen retrieval was done by boiling the 
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slides in 10 mM citric buffer (pH 6.0) for 15 min. Cells undergoing apoptosis were 
detected by immunohistochemical analyses using rabbit polyclonal antibody 
recognizing activated cysteinyl aspartic acid-protease-3 (cleaved caspase-3; Cell 
Signaling, #9661; dilution 1:200). Cell proliferation index was determined by Ki67 
antibody staining (Novocastra Laboratories, #NCL-Ki67p; 1:1,000 dilution). The 
primary antibodies were incubated with deparaffinized sections for 1 hr. at room 
temperature.  Sections were subsequently incubated for 30 min. at room temperature 
with biotinylated secondary antibody and subsequently detected with the ABC Elite 
kit (Vector Laboratories, Burlingame, CA) and 3,3'-diaminobenzidine (Sigma, St. 
Louis, MO) as substrate. 
Analyses of apoptosis and proliferation in tumors.  Apoptotic and proliferation 
indices were determined essentially as described previously (Zhou et al., 2006). 
Briefly, images were captured with a SPOT-RT digital camera (Diagnostic 
Instruments, Inc., Sterling Heights, MI) using 40x objective under a Zeiss Axioskop 2 
Plus microscope. In all experiments 10 images with area 10,384 µm2were captured for 
each slide and transferred to Photoshop 6.0. 2,000 cells were counted in each 
experiment after overlaying a grid. 
Cell lines.  Cell lines with varying FABP5/CRABP-II ratios were generated from 
mammary tumors of MMTV-neu, MCRABP-II-/- and MTgCRABP-II  mice. Tumors 
were collected from all mouse cohorts after reaching a volume of 0.524 cm3, and cell 
lines were generated as previously described (Elson and Leder, 1995).  Briefly, 
tumors were removed, rinsed several times in PBS, and placed in a dish containing 
0.05% trypsin and 0.02% EDTA. Tumors were finely minced with a scalpel, pipetted 
up-and-down 6-7 times, and placed in an incubator for 15 min. at 37oC.  The process 
was repeated twice.  The contents of the dish was placed in a 50 ml tube, allowed to 
settle, and the supernatant removed.  Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin 
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was added to a volume of 25 ml.  Mixture was centrifuged and the pellet resuspend in 
fresh media, transferred to a flask, and cells were grown undisturbed for 24 hr.  Cells 
were passaged 25 times prior to experimentation.  Cells were grown in DMEM 
supplemented with 10% charcoal-treated newborn bovine calf serum (Cocalico 
Biologicals Inc., Reamstown, Pa.), 2 mM glutamine, 100 units/ml penicillin, and 100 
µg/ml streptomycin. 
BrdU cell proliferation assay.  Cells were seeded in 96 well plates in DMEM 
supplemented with 2% charcoal-treated FBS and grown overnight.  Cells were treated 
with 1 µM RA for 24 hr. and analyzed using the BrdU cell proliferation assay 
(Calbiochem). 
Statistical analyses. Statistical analyses was carried out using Prism 3.02 (Graphpad, 
Inc., San Diego, CA) software. Survival fractions were calculated using the Kaplan-
Meier method. Survival curves were compared by log rank Mantel-Haenszel tests. 
Means were compared by estimation of the two-tailed P with unpaired t tests.   
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CHAPTER FOUR 
 
GENERAL DISCUSSION 
 
Studies described in this dissertation aimed to delineate the molecular basis for the 
ability of retinoic acid (RA) to evoke opposing activities in different cells.  This work 
focused on understanding the roles of the two RA nuclear receptors, RAR and 
PPARβ/δ, and the two RA-binding proteins, CRABP-II and FABP5, in regulating 
cellular responses to their ligand.   
It is well established that RA, the active metabolite of vitamin A, influences 
biological processes by activating the retinoic acid receptors (RARs) (Chambon 1996; 
Donato and Noy 2005). Transcriptional activation of RAR has been shown to trigger 
differentiation, cell cycle arrest, and apoptosis. Accordingly, RA displays pronounced 
anticarcinogenic activities and is used or is being tested as a chemotherapeutic agent 
in several forms of human cancers (Soprano, Qin et al. 2004). Previous work from 
this laboratory revealed that CRABP-II, an intracellular lipid binding protein, 
functions to deliver RA to RAR in the nucleus, thus enhancing the receptor’s 
transcriptional ability. Consequently, CRABP-II sensitizes carcinoma cells to the 
growth inhibitory activity of RA, an effect that was found mainly from induction of 
apoptosis (Budhu and Noy 2002; Manor, Shmidt et al. 2003; Donato and Noy 2005).  
However, other observations demonstrated that, under some circumsatnces, 
RA activates pro-proliferate activities, and that these activities appear to be mediated 
through an RAR-independent pathway. A clue to the basis of this paradoxical activity 
stemmed from our previous observations that RA can activate a different nuclear 
receptor, namely PPARβ/δ.  It was thus shown that RA binds to PPARβ/δ with a Kd 
of 15 nM, about an order of magnitude higher affinity than that displayed by PPARα 
and PPARγ (Shaw, Elholm et al. 2003). Accordingly, in the context of a reporter 
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construct, RA selectively activates PPARβ/δ but not other PPAR isotypes. Hence, 
this data suggests the possibility that, in some cells, RA may activate transcription not 
only through RAR but also through PPARβ/δ.   
The observations that RA can activate both RAR and PPARβ/δ raised the 
questions of the factors that regulate the dual activity of this hormone. Previous 
studies have shown that RA is delivered to RAR by the intracellular lipid-binding 
protein CRABP-II.  We show here, that, in a manner similar to that found for the 
cooperation of CRABP-II with RAR, this hormone is delivered to PPARβ/δ by 
another intracellular lipid-binding protein, namely, FABP5. Hence, the partitioning of 
RA between its two receptors is controlled by its two binding proteins.  This behavior 
was found to lead to remarkable biological consequences.  For example, we showed 
that, in keratinocytes, which express a high level of FABP5, RA activates PPARβ/δ 
and that the activation results in upregulation of the survival factor PDK1.  
Consequently, RA protects these cells from apoptosis.  Conversely, in MCF-7 
mammary carcinoma cells, which express a high level of CRABP-II, RA activates 
RAR and thus triggers apoptosis.  Moreover, we showed that modulating the relative 
expression of the two binding proteins profoundly changes the biological activity of 
RA.  Hence, increasing the CRABP-II/FABP5 ratio in keratinocytes inverts the 
response of these cells and converts RA from a survival factor to a pro-apoptotic 
agent.  Correspondingly, decreasing the ratio in MCF-7 cells converts RA from an 
apoptotic to an anti-apoptotic signal in these cells.  
To examine whether CRABP-II and FABP5 control biological responses to 
RA in vivo, we used the mammary carcinoma mouse model MMTVneu.  Assessment 
of the expression levels of RA-receptors in MMTV-neu tumors showed that PPARβ/δ 
levels remain unchanged and RAR is somewhat down-regulated upon tumorigenesis.  
Strikingly, tumor development was accompanied by marked down regulation of 
CRABP-II and an elevated level of FABP5.  We hypothesized that RA-induced 
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proliferative responses in this tumors originated from the disregulation of the binding 
proteins which, in turn, directs RA to PPARβ/δ.  To investigate this hypothesis, we 
generated MMTV-neu mouse models with varied expression ratio of the two binding 
proteins.  Examination of tumors that arise in these models revealed that the 
expression of three PPARβ/δ target genes was significantly reduced in the presence 
of a low FABP5/CRABP-II ratio, and was upregulated in the absence of CRABP-II.  
In contrast, the direct RAR target genes caspase 9 and BTG2 were markedly 
upregulated upon over-expression of CRABP-II, and their expression decreased in 
mice lacking this binding protein. Accordingly, measurements of tumors in these 
mouse models showed that tumor growth in the CRABP-II-null mouse model was 
significantly facilitated, while mammary over-expression of CRABP-II markedly 
delayed tumor growth.   
 
In agreement with previous studies of CRABP-II over-expression in the 
MMTV-neu mouse model (Manor, Shmidt et al. 2003), we demonstrated a significant 
decrease in proliferation in mice over-expressing CRABP-II, and a slight increase in 
proliferation in the CRABP-/- tumor. This behavior could be traced to a markedly 
higher apoptotic index in mammary tumors arising from mice overexpressing 
CRABP-II compared to either the CRABP-II-null mice or the MMTV-neu controls.  
The role of altering the CRABP-II/FABP5 ratio in regulating cellular responses to RA 
was further demonstrated by utilizing cell lines generated from tumors that developed 
in MMTV-neu mice with varying FABP5/CRABP-II ratios.  The data showed that 
cells generated from MMTV-neu mice with transgenic mammary over-expression of 
CRABP-II and from CRABP-II-/- mice retained the binding protein expression 
profiles observed in vivo. Also similarly to the in vivo behavior, CRABP-II-null cells 
displayed a decreased expression of the RAR target gene Cyp26a, and an increased 
expression of the PPARβ/δ target PDK1 as compared with cells over-expressing this 
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binding protein.  Furthermore, RA treatment upregulated the expression of the RAR 
target gene in cells with a high CRABP-II level, but induced the PPARβ/δ target in 
CRABP-II-/- cells. These results are the first in vivo demonstration of the importance 
of  the CRABP-II/FABP5 ratio in regulating the transcriptional activity of RAR and 
PPARβ/δ, and thus the biological responses to their common ligand, RA.   
The findings that a high FABP5/CRABP-II ratio directs RA to PPARβ/δ, and 
that, under such circumstances, RA protects cells against apoptosis and enhances 
proliferation suggest that while CRABP-II functions as a tumor suppressor, FABP5 
may be an oncogene.  Future studies will aim to determine whether this is the case 
and whether ablation of FABP5 or chemical inhibition of this protein may suppress 
tumor growth.  In addition, it would be of great interest to explore whether 
disregulation of expression of these iLBPs accompanies tumorigenesis in cancers 
other than the mammary cancer models used in the present work.  Hence, strategies 
that target the two binding proteins may dramatically reduce the doses of RA needed 
for efficacious treatment, and bypass both the RA-resistance of tumors and the 
toxicity barrier encountered in current therapies. 
Importantly, PPARβ/δ, in addition to its proliferative roles explored here, also 
participates in various metabolic functions. Of special interest in regard to this is the 
recent reports that activation of this receptor is protective against insulin resistance 
and adipocity, activities that are mediated by functions of the receptor in muscle and 
adipose tissue (Wang et al. 2003; Wang, Zhang et al. 2004; Lee, Olson et al. 2006) . 
While we find here that RA can function as an endogenous ligand for this receptor, 
questions remain as to whether this hormone participates in regulating the metabolic 
functions of PPARβ/δ in muscle and adipose tissue. Finally, a key insight provided 
by our work concerns the importance of directed ligand transport in nuclear receptor 
activation. Future studies of this issue will aid in the understanding the pleiotropic 
effects of members of the nuclear receptor superfamily and their various ligands.  
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